Hyaluronidase 2 antibodies and methods of use
Hyaluronidase 2 antibodies conjugated with cytotoxic agents effectively target Hyal2, addressing tumor resistance and immune evasion, enhancing cancer immunotherapy efficacy.
Patent Information
- Application Number
- PCT/US2026/028714
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-18
- Publication Date
- 2026-11-19
AI Technical Summary
Cancer immunotherapies face challenges with resistance and relapse due to tumor stroma components, particularly enhanced hyaluronidase 2 (Hyal2) activity leading to HA degradation, promoting tumor growth and immune evasion.
Development of Hyaluronidase 2 antibodies conjugated with cytotoxic agents to target and inhibit Hyal2, reducing tumor-supporting factors and enhancing immune response.
Hyal2-ADCs demonstrate dose-dependent tumor growth inhibition and improve the efficacy of immune checkpoint inhibitors, leading to tumor regression in animal models.
Smart Images

Figure US2026028714_19112026_PF_FP_ABST
Abstract
Description
HYALURONIDASE 2 ANTIBODIES AND METHODS OF USECROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to United States Provisional Application Serial Number 63 / 806,859, filed May 16, 2025, the contents which is hereby incorporated by reference.INCORPORATION BY REFERENCE OF THE SEQUENCE LISTING
[0002] This application contains, as a separate part of disclosure, a Sequence Listing in computer-readable form (Filename: 70826_SeqListing.xml; Size: 17,705 bytes; Created: May 11, 2026) which is incorporated by reference herein in its entirety.FIELD OF THE INVENTION
[0003] The present invention concerns the field of cancer therapeutics.BACKGROUND
[0004] Cancer immunotherapies, such as immune checkpoint inhibitors, have made a breakthrough in the treatment of various cancer types. However, depending on the cancer type, more than half of treated patients are either resistant to immunotherapy or eventually relapse. One of the biggest challenges for cancer immunotherapy is to understand the mechanisms of resistance and develop effective approaches to overcome them (1-7).
[0005] Tumor stroma plays a major role in tumor growth and is comprised of both cellular and extracellular components. The extracellular matrix (ECM) in tumors includes proteoglycans and glycans such as hyaluronan (HA). HA is a member of the glycosaminoglycan family of polysaccharides, synthesized at the cell surface as a large polysaccharide polymer with very high molecular weight (2x105 to 10x107 Da). Tumor growth is associated with increased expression of hyaluronic acid synthases (HAS) and enhanced HA production (8, 9). HA has been implicated in regulating a variety of cellular functions in tumor cells and tumor-associated stromal cells, suggesting that altered HA content can influence tumor growth and malignancy at multiple levels (8, 10, 11). Importantly, increased HA production in cancer is associated with enhanced HA degradation due to an increased expression / activity of hyaluronidases (Hyal), particularly Hyall and Hyal2 (12, 13).
[0006] Hyaluronidase 2 (Hyal2) is a membrane-bound enzyme that mediates the degradation of extracellular HA. Up-regulated Hyal2 expression is found in several solid cancers including breast, bladder, brain, and esophageal cancers (14-19). The enhanced breakdown of extracellular HA in tumors leads to the accumulation of HA fragments with low molecular weight, promoting elevated production of tumor-supporting factors including inflammatory cytokines, chemokines, and angiogenic factors via TLR2 / TLR4 signaling (20-22). A recent study found that the progression of human bladder cancer is associated with the increased presence of Hyal2-expressing myeloid cells in peripheral blood and cancer tissue (17). In healthy subjects, this cell subset predominantly resides in the bone marrow. However, tumor growth promotes the recruitment of bone marrow-derived Hyal2+ myeloid cells to the tumor vicinity, where these cells become involved in ECM remodeling via enhanced degradation of extracellular HA, fueling tumor growth by stimulating cancer inflammation, angiogenesis, and immune evasion (17, 23).SUMMARY
[0007] In one aspect, the disclosure provides an antibody or antigen binding fragment thereof that binds to Hyaluronidase 2 and comprises a set of 6 CDRs set forth in SEQ ID NOs: 2-7.
[0008] In another aspect, the disclosure provides an antibody or antigen binding fragment thereof that binds to Hyaluronidase 2 comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), wherein the CDR-H1, CDR-H2, and CDR-H3 are present in a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 8 and wherein the CDR-L1, CDR-L2, and CDR-L3 are present in a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 9.
[0009] In another aspect, the disclosure provides is an antibody-drug conjugate comprising an antibody described herein conjugated to a cytotoxic agent. In some embodiments, the cytotoxic agent is a dihydrofolate reductase inhibitor, a thymidylate synthase inhibitor, a DNA intercalator, a DNA cleaver, a topoisomerase inhibitor, anthracycline, vinca, mitomycin, bleomycin, a cytotoxic nucleoside, a pteridine, a diynene, a podophyllotoxin, a dolastatin, a maytansinoid, a differentiation inducer, or a taxol. In some embodiments, the cytotoxic agent is a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent is methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin, doxorubicin, mitomycin C, mitomycin A, caminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vinblastine, vincristine, vindesine, taxanes including taxol, taxotere retinoic acid, butyric acid, N8-acetyl spermidine, camptothecin, calicheamicin, esperamicin, ene-diynes, duocarmycin A, duocarmycin SA, calicheamicin, camptothecin, maytansinoids (including DM1), monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), or maytansinoids (DM4).
[0010] In some embodiments, the antibody is conjugated with Doxorubicin, Docetaxel (Taxotere), Cisplatin, Gemcitabine, Carboplatin, Etoposide, Cyclophosphamide, Epirubicin, Vincristine, Methotrexate, 5-fluoroucil, or Mitomycin C.
[0011] In some embodiments, the antibody is conjugated with PNU anthracycline, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), duocarmycin, calicheamicin, pyrrolobenzodiazepine, or SN-38.
[0012] Methods of treating cancer in a subject in need thereof comprising administering an antibody-drug conjugate to the subject are also contemplated.
[0013] The foregoing summary is not intended to define every aspect of the invention, and additional aspects are described in other sections, such as the Detailed Description. The entire document is intended to berelated as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. With respect to aspects of the invention described or claimed with "a” or "an,” it should be understood that these terms mean "one or more” unless context unambiguously requires a more restricted meaning. The term "or” should be understood to encompass items in the alternative or together, unless context unambiguously requires otherwise. If aspects of the invention are described as "comprising” a feature, embodiments also are contemplated "consisting of' or "consisting essentially of' the feature.BRIEF DESCRIPTION OF THE FIGURES
[0014] FIGs 1A-1E. Detection of Hyal2 expression in both tumor-associated myeloid cells and bladder cancer cells. FIG. 1A: Detection of Hyal2+PD-L1 + cell subset in murine bladder tumors. Organotypic MBT2 tumor tissue slice culture was prepared as described in Methods. On day 7 cultures were fixed with 4% formaldehyde, stained for Hyal2, PD-L1, and DAPI, and analyzed by immunofluorescent microscope. FIG 1B: Tumor-infiltrating myeloid cells co-express Hyal2 and PD-L1. Single-cell MBT2 tumor suspension was prepared using mechanical and enzymatic digestion. CD11b+ myeloid cells were isolated from the MBT2 tumor cell suspension using MACS columns according to manufacturer protocol (Miltenyi Biotec, Auburn, CA) and stained for expression of Hyal2, PD-L1 and DAPI. FIG 10: Analysis of murine Hyal2+ myeloid cells using single-cell RNAseq. The Hyal2+CD11b+ MDSCs were isolated from the spleen of mice bearing syngeneic MBT2 bladder tumors. To define the transcriptional signature of Hyal2+ myeloid cells, the scRNAseq library was prepared using the 10X Genomics platform and the Chromium Single Cell 3' v3 kit and was subsequently sequenced on an Illumina NovaSeq sequencer using an S4 flow cell sorter at ICBR, University of Florida. Raw sequencing reads were converted to gene-barcode matrices using the package Cell Ranger (v1.3.1, 10X Genomics), followed by analyses in R (v3.6.3) using the package Seurat. The distribution of cells is shown as 8 cell clusters using UMAP clustering (FIG. 1A) and gene expression as a heatmap (FIG. 1B). FIG 1D: Expression of Hyal2 in bladder tumor cell lines using Western Blotting. Cell lysates were prepared, and then lysed in M-PER mammalian protein extraction reagent containing protease and phosphatase inhibitors. Whole-cell lysates were subjected to 10% SDS-PAGE and blotted onto PVDF membranes. Results were visualized by chemiluminescence detection using a SuperSignal West Pico substrate. FIG 1E: MTT assay. Murine MBT-2 and human SW780 bladder cancer cell lines were seeded in 96-well microplates at a density of 1 x 104cells / well with 100 pl of culture media per well, and then treated with serial concentrations of Hyal2-PNU ADC or control IgG-PNU ADC for 96 hours (n = 4). Cell viability was then assessed using a thiazolyl blue tetrazolium bromide following the manufacturer's protocol. The signals were measured with a UV / vis microplate spectrophotometer (BioTek). Percent cell viability was calculated as (test CD570 / nontreated CD570) x 100%. The IC 50 was calculated by fitting data to nonlinear regression with GraphPad Prism 5 software.
[0015] FIGs 2A-2D. Ex vivo tumor tissue treatment with Hyal2A-ADC abrogates the development of PD-L1 macrophages. FIG. 2A: Gr-1+ cells isolated from naive bone marrow were cultured with tumor-conditioned medium (TCM) in the presence of control IgG-ADC or Hyal2-ADC. On day six, cultured cells were fixed with 4%formaldehyde solution and stained with Abs against PD-L1 (red) and F4 / 80 (green). Cells were imaged with an EVOS FL immunofluorescent microscope. Representative images are shown. FIG. 2B: Quantification of PD-L1 cells in bone marrow-derived Gr1-1 + myeloid cells treated with IgG-ADC or Hyal2A-ADC is shown. Average means ± SD are shown; *, P<0.05. FIG. 2 C: Organotypic MBT2 tumor tissue slice cultures were prepared as described in the section Methods. IgG-ADC or Hyal2A-ADC (250 ng / ml) was added to the tissue cultures immediately after tissue cutting the tumor slices. Five days later, cultures were fixed with 4% formaldehyde, stained for PD-L1 and DAPI, and analyzed by immunofluorescent microscope. FIG 2D: Quantification of PD-L1 + expressing cells in tissue cultures treated with IgG-ADC or Hyal2A-ADC. Average means ± SD are shown; *, P<0.05
[0016] FIGs 3A and 3B. Administration of Hyal2A-ADC results in dose-dependent inhibition of tumor growth. FIG. 3A: C3 / H mice were inoculated with syngeneic murine bladder MBT2 tumor cells (s.c., 5x105cells / per mouse). On day 8 after tumor cell inoculation, when tumors reached 6-8 mm in diameter, mice were randomly divided into 3 groups and injected i.v. with: Group 1: Vehicle (PBS); Group 2: control IgG-ADC; Group 3:Hyal2A-ADC (35 pig / mouse, 70 pig / mouse or 100 pig / mouse. Injections were repeated 6-7 days later. Tumor size was measured using a caliper every three days. FIG. 3B: Kaplan-Meier surviving plots for treated mice are shown. Statistical analysis of Kaplan-Myers survival plots was conducted using the Mantel-Cox long-rank test.
[0017] FIG. 4A and 4B. Combination treatment of Hyal2A-ADC and anti-PD 1 antibody results in tumor regression of established bladder tumors. FIG. 4A: Left panel. C3 / He mice were inoculated with syngeneic murine bladder MBT2 tumor cells (s.c., 5x105cells / per mouse). On day 7 after tumor cell inoculation, when tumors reached 5-7 mm in diameter (<200 mm3 in volume), mice were randomly divided into 4 groups and injected i.v. with: control IgG-ADC + isotype IgG; Hyal2A-ADC alone (50 pig / mouse); or anti-PD 1 mAbs alone; or combination Hyal2A-ADC +anti-PD1 mAbs. In total, 2 injections of ADC (days 7 and 13), and 3 injections of anti-PD 1 mAbs (days 7, 10, and 13). Central panel. On day 10 after tumor cell inoculation, when tumors reached 7-9 mm in diameter (200-260 mm3 in volume), mice were randomly divided into 4 groups and injected i.v. with: control IgG-ADC + isotype IgG; Hyal2A-ADC (100 pig / mouse); or anti-PD 1 mAbs antibody alone; or combination Hyal2A-ADC+anti-PD1 mAbs. Tumor size was measured using a caliper every three days. In total, 2 injections of ADC (days 10 and 16), and 3 injections of anti-PD1 mAbs (days 10, 13, and 16). Right panel. Combination treatment of Hyal2A-ADC and anti-CTLA-4 mAbs results in tumor regression of established MB49 bladder tumors. C57 / BL6 mice were inoculated with syngeneic murine bladder MB49 tumor cells (s.c., 5x103cells / per mouse). On day 5 after tumor cell inoculation, when tumors reached 4-6 mm in diameter (<200 mm3 in volume), mice were randomly divided into 4 groups and injected i.v. with: control IgG-ADC + isotype IgG; Hyal2A-ADC alone (100 pig / mouse); or anti-CTLA-4 mAbs alone (200 pig / mouse); or combination Hyal2A-ADC + CTLA-4 mAbs. In total, 2 injections of ADC (days 5 and 10), and 4 injections of anti-CTLA-4 mAbs (days 5, 8, 11, and 14). FIG. 4B: Kaplan-Meier surviving curves for mice with early-stage MBT2 tumors (<200 mm3). Tumor-bearing mice were treated as described in FIG.4A. The percentage of tumor-free mice is shown.
[0018] FIGs. 5A-5D. Expression of Hyal2 in human bladder cancer. FIG. 5A: Effect of Hyal2A-ADC on the growth of SW780 human bladder tumors. Survival curve for SCID mice with implanted human SW780 tumors. Fifteen NOD-SCID mice were subcutaneously inoculated with human SW780 bladder cancer cells (s.c. 2x106cells / per mouse). On day 21 after tumor cell inoculation, when tumors reached 8-10 mm in 220-300 mm3 in volume, mice were randomly divided in three groups and injected with: 1) vehicle (PBS); 2) control IgG-ADC; 3) or with Hyal2A-ADC (100 pig / mouse). Tumor size was measured using a Vernier caliper twice a week. In total, 2 injections of ADC (days 21 and 27). Percent of tumor-free mice is shown. FIG. 5B and FIG. 5C: Detection of Hyal2+ cells in human bladder cancer tissue using DAB staining. FFPE bladder tissues were stained using primary anti-Hy al2 monoclonal antibodies and secondary HRP-conjugated antibodies. Secondary antibodies and DAB staining kit were purchased from Abeam. Hyal2-positive cells can be seen as brown-colored cells. FIG.5D: Detection of tissue-infiltrating Hyal2+PD-L1 + cell subset using immunofluorescent staining. Human cancer bladder tissue slides (FFPE) were stained with fluorochrome-conjugated anti-Hyal2 (red), anti-PD-L1 (green) or CD31 (blue) antibodies. Representative images are shown.
[0019] FIG. 6A-6B. Exposure of myeloid cells to tumor-derived factors stimulates Hyal2 expression. CD11b myeloid cells were isolated from the peripheral blood of patients with cancer and cultured in complete culture media for 48 hours in the presence or absence of a tumor-conditioned medium (TOM). T24 human cancer cell line-derived culture supernatant was a source of TOM. FIG. 6A:Collected cells were fixed with 4% formaldehyde and stained with anti-Hyal2A (red) and CD11b (green) antibodies. FIG. 6B: Tumor-derived factors up-regulate the expression of Hyal2 in myeloid cells. CD11b myeloid cells were isolated from the peripheral blood of patients with cancer and cultured in complete culture media for 48 hours in the presence or absence of (TOM). Collected cells were lysed and expression of Hyal2 was measured using Western Blotting. FIG. 6C: Dual tumor-promoting function of Hyal2+PD-L1 + myeloid cells. Tumor-recruited Hyal2+ MDSCs differentiate into immunosuppressive PD-L1 + TAMs that inhibit T cell immune response via PD-L1-PD1 mechanism. In addition, Hyal2+ myeloid cells contribute to ECM remodeling via Hyal2-mediated HA degradation.
[0020] FIG. 7. In vivo targeting Hyal2 with ADC modulates immunosuppressive tumor microenvironment and reduces number of PD-L1 + TAMs. Tumor tissues were collected from control (IgG-ADC) and Hyal2A-ADC-treated tumor-bearing mice six days later after single injection of ADC (i.v. 70 pig / mouse, n=4). Tissues were processed to prepare single-cell suspension using mechanical and enzymatic digestion and then analyzed for expression of PD-L1 and CD8. Average means ± SD are shown. *, P<0.05.
[0021] FIGs. 8A and 8B. Hyal2A-PNU ADC is superior to Hyal2B-PNU ADC. C3 / He mice were inoculated with syngeneic murine bladder MBT2 tumor cells (s.c., 0.5x106cells / mouse). On day 7m when tumors became palpable (6-7 mm in diameter), mice were injected once i.v. with vehicle (PBS), control IgG-PNU conjugates, Hyal2A-PNU ADC (FIG. 8A) or Hyal2B-PNU ADC (FIG. 8B) at a dose of 100 mg / mouse.DETAILED DESCRIPTION
[0022] The present disclosure is based on the discovery that targeting Hyal2 with a Hyal2-antibody-drug conjugate (Hyal2-ADC) resulted in a dose-dependent tumor growth inhibition while simultaneously eliminating immunosuppressive myeloid cells, markedly improving the therapeutic efficacy of anti-PD1 and anti-CTLA therapy in two syngeneic animal models of bladder cancer. Co-administration of immune checkpoint inhibitors with Hyal2-ADC led to tumor regression in 80-100% of mice with established early-stage and advanced tumors.
[0023] The term "antibody” refers to an intact immunoglobulin molecule (including polyclonal, monoclonal, chimeric, humanized, and / or human versions having full length heavy and / or light chains). The antibody may be any type of antibody, i.e., immunoglobulin, known in the art. In exemplary embodiments, the antibody is an antibody of class or isotype IgA, IgD, IgE, IgG, or IgM. In exemplary embodiments, the antibody described herein comprises one or more alpha, delta, epsilon, gamma, and / or mu heavy chains. In exemplary embodiments, the antibody described herein comprises one or more kappa or light chains. In exemplary aspects, the antibody is an IgG antibody and optionally is one of the four human subclasses: lgG1, lgG2, lgG3 and lgG4. Also, the antibody in some embodiments is a monoclonal antibody. In other embodiments, the antibody is a polyclonal antibody. In some aspects, the antibody is a chimeric or a humanized antibody. The term "humanized" when used in relation to antibodies refers to antibodies having at least CDR regions from a non-human source and which are engineered to have a structure and immunological function more similar to true human antibodies than the original source antibodies. For example, humanizing can involve grafting CDRs from a non-human antibody, such as a mouse antibody, into a human antibody framework. Humanizing also can involve select amino acid substitutions to make a non-human sequence look more like a human sequence.
[0024] "Specifically binds” as used herein means that the antibody (or antigen binding fragment) preferentially binds an antigen (e.g., human hyaluronidase 2 (Genbank Accession No. NP_003764) over other proteins. In some embodiments, "specifically binds” means the antibody has a higher affinity for the antigen than for other proteins. Antibodies that specifically bind an antigen may have a binding affinity for the antigen of less than or equal to 1 x 107M, less than or equal to 2 x 107M, less than or equal to 3 x 107M, less than or equal to 4 x 107M, less than or equal to 5 x 107M, less than or equal to 6 x 10~7M, less than or equal to 7 x 107M, less than or equal to 8 x 107M, less than or equal to 9 x 107M, less than or equal to 1 x 108M, less than or equal to 2 x 108M, less than or equal to 3 x 10'8M, less than or equal to 4 x 10-8M, less than or equal to 5 x 10-8M, less than or equal to 6 x 10’8M, less than or equal to 7 x 10’8M, less than or equal to 8 x 10’8M, less than or equal to 9 x 10’8M, less than or equal to 1 x 109M, less than or equal to 2 x 10’9M, less than or equal to 3 x 10’9M, less than or equal to 4 x 10’9M, less than or equal to 5 x 10’9M, less than or equal to 6 x 10’9M, less than or equal to 7 x 10’9M, less than or equal to 8 x 10’9M, less than or equal to 9 x 10’9M, less than or equal to 1 x 10’10M, less than or equal to 2 x 10'10M, less than or equal to 3 x 10-10M, less than or equal to 4 x 10-10M, less than or equal to 5 x 10'10M, less than or equal to 6 x 10'10M, less than or equal to 7 x 10-10M, less than or equal to 8 x 10-10M, less than or equal to 9 x 10-10M, less than or equal to 1 x 10'11M, less than or equal to 2 x 10-11M, less than or equal to 3 x 10-11M, less than or equal to 4 x 10-11M, less than or equal to 5 x 10'11M, less than or equal to 6 x 10'11M, less than or equal to 7 x 10-11M, less than or equal to 8 x 10'11M, less than or equal to 9 x 1011M, lessthan or equal to 1 x 10’12M, less than or equal to 2 x 10’12M, less than or equal to 3 x 10’12M, less than or equal to 4 x 10’12M, less than or equal to 5 x 10’12M, less than or equal to 6 x 10’12M, less than or equal to 7 x 10’12M, less than or equal to 8 x 10’12M, or less than or equal to 9 x 1012M. It will be appreciated that ranges having the values above as end points is contemplated in the context of the disclosure. For example, the antibody or antigen binding fragment thereof may bind human hyaluronidase 2 of SEQ ID NO: 1 with an affinity of about 1 x 107M to about 9 x 10 -12M or an affinity of 1 x 109to about 9 x IO12.
[0025] In some or any embodiments, the antibody (or antigen binding fragment) binds to human hyaluronidase 2 of SEQ ID NO: 1, or a naturally occurring variant thereof, with an affinity (Kd) of less than or equal to 1 x 107M, less than or equal to 1 x 108M, less than or equal to 1 x 109M, less than or equal to 1 x 10-10M, less than or equal to 1 x 10'11M, or less than or equal to 1 x 10'12M, or ranging from 1 x 109to 1 xIO10, or ranging from 1 x 1012to about 1 x 1013. Affinity is determined using a variety of techniques, examples of which include an affinity ELISA assay and a surface plasmon resonance (BIAcore) assay.
[0026] "CDR" refers to the complementarity determining region within antibody variable sequences. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term "set of six CDRs " as used herein refers to a group of three CDRs that occur in the light chain variable region and heavy chain variable region, which are capable of binding the antigen. The exact boundaries of CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia & Lesk, J. Mol. Biol. 196:901-917 (1987) and Chothia et al., Nature 342:877-883 (1989)) found that certain sub-portions within Kabat CDRs adopt nearly identical peptide backbone conformations, despite having great diversity at the level of amino acid sequence. These sub-portions were designated as L1, L2 and L3 or H1, H2 and H3 where the "L" and the "H" designates the light chain and the heavy chains regions, respectively.
[0027] In various aspects, the antibody (or antigen binding fragment thereof) comprises at least one CDR sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to a CDR selected from CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 wherein CDR-H1 has the sequence given in SEQ ID NO: 2, CDR-H2 has the sequence given in SEQ ID NO: 3, CDR-H3 has the sequence given in SEQ ID NO: 4, CDR-L1 has the sequence given in SEQ ID NO: 5, CDR-L2 has the sequence given in SEQ ID NO: 6 and CDR-L3 has the sequence given in SEQ ID NO: 7. In various aspects, the antibody (or antigen binding fragment thereof) comprises a CDR-H1 having the sequence given in SEQ ID NO: 2 with 3, 2, or 1 amino acid substitutions therein; CDR-H2 having the sequence given in SEQ ID NO: 3 with 3, 2, or 1 amino acid substitutions therein; CDR-H3 having the sequence given in SEQ ID NO: 4 with 3, 2, or 1 amino acid substitutions therein; CDR-L1 having the sequence given in SEQ ID NO: 5 with 3, 2, or 1 amino acid substitutions therein; CDR-L2 having the sequence given in SEQ ID NO: 6 with 3, 2, or 1 amino acidsubstitutions therein and CDR-L3 having the sequence given in SEQ ID NO: 7 with 3, 2, or 1 amino acid substitutions therein. The anti-hyaluronidase 2 antibody, in various aspects, comprises two of the CDRs, three of the CDRs, four of the CDRs, five of the CDRs or all six of the CDRs. In some embodiments, the antihyaluronidase 2 antibody comprises a set of six CDRs as follows: CDR-H1 of SEC ID NO: 2, CDR-H2 of SEC ID NO: 3, CDR-H3 of SEC ID NO: 4, CDR-L1 of SEC ID NO: 5, CDR-L2 of SEC ID NO: 6 and CDR-L3 of SEQ ID NO: 7.
[0028] In various aspects, the antibody (or antigen binding fragment thereof) comprises at least one CDR sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to a CDR selected from CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 wherein CDR-H1 has the sequence given in SEQ ID NO: 12, CDR-H2 has the sequence given in SEQ ID NO: 13, CDR-H3 has the sequence given in SEQ ID NO: 14, CDR-L1 has the sequence given in SEQ ID NO: 15, CDR-L2 has the sequence given in SEQ ID NO: 16 and CDR-L3 has the sequence given in SEQ ID NO: 17. In various aspects, the antibody (or antigen binding fragment thereof) comprises a CDR-H1 having the sequence given in SEQ ID NO: 12 with 3, 2, or 1 amino acid substitutions therein; CDR-H2 having the sequence given in SEQ ID NO: 13 with 3, 2, or 1 amino acid substitutions therein; CDR-H3 having the sequence given in SEQ ID NO: 14 with 3, 2, or 1 amino acid substitutions therein; CDR-L1 having the sequence given in SEQ ID NO: 15 with 3, 2, or 1 amino acid substitutions therein; CDR-L2 having the sequence given in SEQ ID NO: 16 with 3, 2, or 1 amino acid substitutions therein and CDR-L3 having the sequence given in SEQ ID NO: 17 with 3, 2, or 1 amino acid substitutions therein. The anti-hyaluronidase 2 antibody, in various aspects, comprises two of the CDRs, three of the CDRs, four of the CDRs, five of the CDRs or all six of the CDRs. In some embodiments, the antihyaluronidase 2 antibody comprises a set of six CDRs as follows: CDR-H1 of SEQ ID NO: 12, CDR-H2 of SEQ ID NO: 13, CDR-H3 of SEQ ID NO: 14, CDR-L1 of SEQ ID NO: 15, CDR-L2 of SEQ ID NO: 16 and CDR-L3 of SEQ ID NO: 17.
[0029] In some or any embodiments, the antibody (or fragment thereof) comprises a heavy chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 8 and / or a light chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 9. In various aspects, the difference in the sequence compared to SEQ ID NO: 8 or SEQ ID NO: 9 lies outside the CDR region in the corresponding sequences.
[0030] In some or any embodiments, the antibody (or antigen binding fragment) comprises a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 8 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 9.
[0031] In some or any embodiments, the antibody (or fragment thereof) comprises a heavy chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%,95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 20 and / or a light chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 21. In various aspects, the difference in the sequence compared to SEQ ID NO: 20 or SEQ ID NO: 21 lies outside the CDR regions in the corresponding sequences.
[0032] In some or any embodiments, the antibody (or antigen binding fragment) comprises a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 20 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 21.
[0033] In some or any embodiments, the antibody (or fragment thereof) comprises a heavy chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 22 and / or a light chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 23. In various aspects, the difference in the sequence compared to SEQ ID NO: 22 or SEQ ID NO: 23 lies outside the CDR regions in the corresponding sequences.
[0034] In some or any embodiments, the antibody (or antigen binding fragment) comprises a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 22 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 23.
[0035] In some or any embodiments, the antibody (or fragment thereof) comprises a heavy chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 24 and / or a light chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 25. In various aspects, the difference in the sequence compared to SEQ ID NO: 24 or SEQ ID NO: 25 lies outside the CDR regions in the corresponding sequences.
[0036] In some or any embodiments, the antibody (or antigen binding fragment) comprises a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 24 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 25.
[0037] In some or any embodiments, the antibody (or fragment thereof) comprises a heavy chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 26 and / or a light chain variable region comprising an amino acid sequence having at least 75% identity (e.g., at least 75%, 80%, 85%, 90%, 95% or 100% identity) to the amino acid sequence set forth in SEQ ID NO: 27. In various aspects, the difference in the sequence compared to SEQ ID NO: 26 or SEQ ID NO: 27 lies outside the CDR regions in the corresponding sequences.
[0038] In some or any embodiments, the antibody (or antigen binding fragment) comprises a heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 26 and a light chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 27.
[0039] Antigen binding fragments of anti-hyaluronidase 2 antibodies described herein are also contemplated. The antigen binding fragment can be any part of an antibody that has at least one antigen binding site, and the antigen binding fragment may be part of a larger structure (an "antibody product”) that retains the ability of the antigen binding fragment to recognize hyaluronidase 2. For ease of reference, these antibody products that include antigen binding fragments are included in the disclosure herein of "antigen binding fragment.” Examples of antigen binding fragments, include, but are not limited to, Fab, F(ab')2, a monospecific or bispecific Fab?, a trispecific Faba, scFv, dsFv, scFv-Fc, bispecific diabodies, trispecific triabodies, minibodies, a fragment of IgNAR (e.g., V-NAR), a fragment of hcIgG (e.g., VhH), bis-scFvs, fragments expressed by a Fab expression library, and the like. In exemplary aspects, the antigen binding fragment is a domain antibody, VhH domain, V-NAR domain, VH domain, VL domain, or the like. Antibody fragments of the disclosure, however, are not limited to these exemplary types of antibody fragments. In exemplary aspects, antigen binding fragment is a Fab fragment. In exemplary aspects, the antigen binding fragment comprises two Fab fragments. In exemplary aspects, the antigen binding fragment comprises two Fab fragments connected via a linker. In exemplary aspects, the antigen binding fragment comprises or is a minibody comprising two Fab fragments.
[0040] A domain antibody comprises a functional binding unit of an antibody, and can correspond to the variable regions of either the heavy (VH) or light (VL) chains of antibodies. A domain antibody can have a molecular weight of approximately 13 kDa, or approximately one-tenth of a full antibody. Domain antibodies may be derived from full antibodies such as those described herein.
[0041] In some embodiments, the scFv is attached to a human Fc domain. In some embodiments, the Fc domain does not activate Fc effector functions.
[0042] Suitable methods of making antibodies are known in the art. For instance, standard hybridoma methods are described in, e.g., Harlow and Lane (eds.), Antibodies: A Laboratory Manual, CSH Press (1988), and CA. Janeway et al. (eds.), Immunobiology, 5th Ed., Garland Publishing, New York, NY (2001)). Monoclonal antibodies for use in the methods of the disclosure may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (Nature 256: 495-497, 1975), the human B-cell hybridoma technique (Kosbor et al., Immunol Today 4:72, 1983; Cote et al., Proc Natl Acad Sci 80: 2026-2030, 1983) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R Liss Inc, New York N.Y., pp 77-96, (1985). Alternatively, other methods, such as EBV-hybridoma methods (Haskard and Archer, J. Immunol. Methods, 74(2), 361-67 (1984), and Roder et al., Methods Enzymol., 121, 140-67 (1986)), and bacteriophage vector expression systems (see, e.g., Huse et al., Science, 246, 1275-81 (1989)) are known in the art. Further, methods of producing antibodies in non-human animals are described in, e.g., U.S.Patents 5,545,806, 5,569,825, and 5,714,352, and U.S. Patent Application Publication No. 2002 / 0197266 Al). Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orland! et al (Proc Natl Acad Sci 86: 3833-3837; 1989), and Winter G and Milstein C (Nature 349: 293-299, 1991). If the full sequence of the antibody or antigen-binding fragment is known, then methods of producing recombinant proteins may be employed. See, e.g., "Protein production and purification” Nat Methods 5(2): 135-146 (2008). In some embodiments, the antibodies (or antigen binding fragments) are isolated from cell culture or a biological sample if generated in vivo.
[0043] Phage display also can be used to generate the antibody of the present disclosures. In this regard, phage libraries encoding antigen-binding variable (V) domains of antibodies can be generated using standard molecular biology and recombinant DNA techniques (see, e.g., Sambrook et al. (eds.), Molecular Cloning, A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory Press, New York (2001)). Phage encoding a variable region with the desired specificity are selected for specific binding to the desired antigen, and a complete or partial antibody is reconstituted comprising the selected variable domain. Nucleic acid sequences encoding the reconstituted antibody are introduced into a suitable cell line, such as a myeloma cell used for hybridoma production, such that antibodies having the characteristics of monoclonal antibodies are secreted by the cell (see, e.g., Janeway et al., supra, Huse et al., supra, and U.S. Patent 6,265,150). Related methods also are described in U.S. Patent No. 5,403,484; U.S. Patent No. 5,571,698; U.S. Patent No. 5,837,500; U.S. Patent No. 5,702,892. The techniques described in U.S. Patent No. 5,780,279; U.S. Patent No. 5,821,047; U.S. Patent No. 5,824,520; U.S. Patent No. 5,855,885; U.S. Patent No. 5,858,657; U.S. Patent No. 5,871,907; U.S. Patent No. 5,969,108; U.S. Patent No. 6,057,098; and U.S. Patent No. 6,225,447.
[0044] Antibodies can be produced by transgenic mice that are transgenic for specific heavy and light chain immunoglobulin genes. Such methods are known in the art and described in, for example U.S. Patent Nos. 5,545,806 and 5,569,825, and Janeway et al., supra.
[0045] Methods of testing antibodies for the ability to bind to an epitope of hyaluronidase 2, regardless of how the antibodies are produced, are known in the art and include, e.g., radioimmunoassay (RIA), ELISA, Western blot, immunoprecipitation, surface plasmon resonance (e.g., BIAcore), and competitive inhibition assays (see, e.g., Janeway et al., infra, and U.S. Patent Application Publication No. 2002 / 0197266).
[0046] Antibody fragments that contain the antigen binding, or idiotype, of the antibody molecule may be generated by techniques known in the art. For example, a F(ab')2 fragment may be produced by pepsin digestion of the antibody molecule; Fab' fragments may be generated by reducing the disulfide bridges of the F(ab')2 fragment; and two Fab' fragments which may be generated by treating the antibody molecule with papain and a reducing agent. The disclosure is not limited to enzymatic methods of generating antigen binding fragments; the antigen binding fragment may be a recombinant antigen binding fragment produced by expressing a polynucleotide encoding the fragment in a suitable host cell.
[0047] A single-chain variable region fragments (scFv), which consists of a truncated Fab fragment comprising the variable (V) domain of an antibody heavy chain linked to a V domain of an antibody light chain via a synthetic peptide, can be generated using routine recombinant DNA technology techniques (see, e.g., Janeway et al., supra). Similarly, disulfide-stabilized variable region fragments (dsFv) can be prepared by recombinant DNA technology (see, e.g., Reiter et al., Protein Engineering, 7, 697-704 (1994)).
[0048] Recombinant antibody fragments, e.g., scFvs, can also be engineered to assemble into stable multimeric oligomers of high binding avidity and specificity to different target antigens. Such diabodies (dimers), triabodies (trimers) or tetrabodies (tetramers) are well known in the art, see e.g., Kortt et al., Biomol Eng. 2001 18:95-108, (2001) and Todorovska et al., J Immunol Methods. 248:47-66, (2001).Antibody-Drug Conjugates
[0049] In some embodiments, an antibody described herein is optionally conjugated with cytotoxic agent to form an antibody-drug conjugate (ADCs). In general, ADCs are used in a variety of contexts, including oncology applications, where the use of antibody-drug conjugates for the local delivery of cytotoxic or cytostatic agents allows for the targeted delivery of the drug moiety to tumors, which can allow higher efficacy, lower toxicity, etc. An overview of this technology is provided in Ducry et al., Bioconjugate Chem., 21:5-13 (2010); Carter et al., Cancer J. 14(3):154 (2008); and Senter, Current Opin. Chem. Biol. 13:235-244 (2009), all of which are hereby incorporated by reference in their entirety.
[0050] Generally, conjugation is performed by covalent attachment to an antibody, as further described below, and generally relies on a linker, often a peptide linkage (which, as described herein, may be designed to be sensitive to cleavage by proteases at the target site or not). In addition, linkage of the linker-drug unit (LU-D) can be achieved by attachment to cysteines within the antibody. The number of drug moieties per antibody can change, depending on the conditions of the reaction, and can vary from 1:1 to 10:1 drug:antibody. As will be appreciated by those in the art, the actual number is an average.
[0051] The cytotoxic agent of the ADC can be selected from any of a number of agents, including but not limited to chemotherapeutic agents, growth inhibitory agents, toxins (for example, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (that is, a radioconjugate). The disclosure further provides methods of using the ADCs.
[0052] Drugs for use in the context of the disclosure include cytotoxic drugs, particularly those which are used for cancer therapy. Such drugs include, in general, DNA damaging agents, anti-metabolites, natural products and their analogs. Exemplary classes of cytotoxic agents include the enzyme inhibitors such as dihydrofolate reductase inhibitors, and thymidylate synthase inhibitors, DNA intercalators, DNA cleavers, topoisomerase inhibitors, the anthracycline family of drugs, vinca drugs, mitomycins, bleomycins, cytotoxic nucleosides, the pteridine family of drugs, diynenes, podophyllotoxins, dolastatins, maytansinoids, differentiation inducers, and taxols.
[0053] In some embodiments, an antibody described herein is conjugated with methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin, doxorubicin, mitomycin C, mitomycin A, caminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vinblastine, vincristine, vindesine, taxanes including taxol, taxotere retinoic acid, butyric acid, N8-acetyl spermidine, camptothecin, calicheamicin, esperamicin, ene-diynes, duocarmycin A, duocarmycin SA, calicheamicin, camptothecin, maytansinoids (including DM1), monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), or maytansinoids (DM4) and their analogues.
[0054] In some embodiments, an antibody described herein is conjugated with Doxorubicin, Docetaxel (Taxotere), Cisplatin, Gemcitabine, Carboplatin, Etoposide, Cyclophosphamide, Epirubicin, Vincristine, Methotrexate, 5-fluoroucil, or Mitomycin C.
[0055] In some embodiments, an antibody described herein is conjugated with PNU anthracycline, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), duocarmycin, calicheamicin, pyrrolobenzodiazepine, or SN-38.
[0056] In some embodiments, an antibody described herein is conjugated to a nucleic acid (e.g., an antisense oligonucleotide).Therapeutic Methods
[0057] In another aspect, described herein is a method of treating a cancer associated with elevated circulating levels hyaluronidase 2-positive myeloid cells, the method comprising administering a Hyal2-antibody drug conjugate (Hyal2-ADC) to the subject.
[0058] Exemplary cancers include, but are not limited to, breast cancer, renal cell carcinoma, esophageal cancer, pancreatic cancer, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, bladder cancer, stomach cancer, fibrotic cancer, glioma, malignant glioma, diffuse intrinsic pontine glioma, recurrent childhood brain neoplasm renal cell carcinoma, clear-cell metastatic renal cell carcinoma, kidney cancer, prostate cancer, metastatic castration resistant prostate cancer, stage IV prostate cancer, metastatic melanoma, melanoma, malignant melanoma, recurrent melanoma of the skin, melanoma brain metastases, stage II IA skin melanoma, stage III B skin melanoma, stage NIC skin melanoma, stage IV skin melanoma, malignant melanoma of head and neck, lung cancer, non-small cell lung cancer (NSCLC), squamous cell non-small cell lung cancer, recurrent metastatic breast cancer, hepatocellular carcinoma, Hodgkin's lymphoma, follicular lymphoma, nonHodgkin's lymphoma, advanced B-cell NHL, HL including diffuse large B-cell lymphoma (DLBCL), multiple myeloma, chronic myeloid leukemia, adult acute myeloid leukemia in remission, adult acute myeloid leukemia with Inv(16)(p13.1q22); CBFB-MYH11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); CBFB-MYH11, adult acute myeloid leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1, adult acute myeloid leukemia with t(9;11)(p22;q23); MLLT3-MLL, adult acute promyelocytic leukemia with t(15; 17)(q22;q12); PML-RARA; alkylating agent-related acute myeloid leukemia, chronic lymphocytic leukemia, richter's syndrome, Waldenstrommacroglobulinemia, adult glioblastoma, adult gliosarcoma, recurrent glioblastoma, recurrent childhood rhabdomyosarcoma, recurrent Ewing sarcoma / peripheral primitive neuroectodermal tumor, recurrent neuroblastoma, recurrent osteosarcoma, colorectal cancer, MSI positive colorectal cancer, MSI negative colorectal cancer, nasopharyngeal nonkeratinizing carcinoma, recurrent nasopharyngeal undifferentiated carcinoma, cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma, recurrent cervical carcinoma, stage IVA cervical cancer, stage I VB cervical cancer, anal canal squamous cell carcinoma, metastatic anal canal carcinoma, recurrent anal canal carcinoma, recurrent head and neck cancer, carcinoma, squamous cell of head and neck, head and neck squamous cell carcinoma (HNSCC), ovarian carcinoma, colon cancer, gastric cancer, advanced Gl cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, bone neoplasms, soft tissue sarcoma, bone sarcoma, thymic carcinoma, urothelial carcinoma, recurrent merkel cell carcinoma, stage III merkel cell carcinoma, stage IV merkel cell carcinoma, myelodysplastic syndrome and recurrent mycosis fungoides and Sezary syndrome.
[0059] In some embodiments, the cancer associated with elevated circulating levels hyaluronidase 2-positive myeloid cells is prostate cancer, bladder cancer, breast cancer, brain cancer or lung cancer. In some embodiments, the cancer is bladder cancer.
[0060] In some embodiments, the methods described herein further comprise administering another cancer therapy to the subject. Exemplary cancer therapies include, but are not limited to, a surgical therapy, chemotherapy (e.g., administration of a protein kinase inhibitor or a EGFR-targeted therapy), radiation therapy, cryotherapy, hyperthermia treatment, phototherapy, radioablation therapy, hormonal therapy, immunotherapy, small molecule therapy, receptor kinase inhibitor therapy, anti-angiogenic therapy, cytokine therapy or a biological therapies such as monoclonal antibodies, siRNA, miRNA, antisense oligonucleotides, ribozymes or gene therapy. Without limitation the biological therapy may be a gene therapy, such as tumor suppressor gene therapy, a cell death protein gene therapy, a cell cycle regulator gene therapy, a cytokine gene therapy, a toxin gene therapy, an immunogene therapy, a suicide gene therapy, a prodrug gene therapy, an anti-cellular proliferation gene therapy, an enzyme gene therapy, or an anti-angiogenic factor gene therapy.
[0061] In some embodiments, the cancer therapy comprises chemotherapy. Exemplary chemotherapies include, but are not limited to, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabien, navelbine, famesyl-protein transferase inhibitors, transplatinum, 5-fluorouracil, vincristine, vinblastine and methotrexate, Temazolomide (an aqueous form of DTIC), alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesinsynthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall; dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores, aclacinomysins, actinomycin, authrarnycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholinodoxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalarnycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; taxoids, e.g., paclitaxel and docetaxel gemcitabine; 6-thioguanine; mercaptopurine; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluorometlhylornithine (DMFO); retinoids such as retinoic acid; capecitabine; carboplatin, procarbazine, plicomycin, gemcitabien, navelbine, farnesyl-protein transferase inhibitors, transplatinum; and pharmaceutically acceptable salts, acids or derivatives of any of the above.
[0062] In some embodiments, the cancer therapy is a histone deacetylase inhibitor (e.g., gefitinib or Gleevac).
[0063] In some embodiments, the cancer therapy is radiotherapy. Other factors that cause DNA damage and have been used extensively include what are commonly known as y-rays, X-rays, and / or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also known such as microwaves and UV-irradiation. It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.
[0064] In some embodiments, the cancer therapy is immunotherapy. Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells as well as genetically engineered variants of these cell types modified to express chimeric antigen receptors.
[0065] Exemplary immunotherapies that can be combined with the agonist complexes described herein include immune adjuvants (e.g., Mycobacterium bovis, Plasmodium falciparum, dinitrochlorobenzene and aromatic compounds) (U.S. Pat. Nos. 5,801,005; 5,739,169; Hui and Hashimoto, 1998; Christodoulides et al., 1998), cytokine therapy (e.g., interferons .alpha., .beta, and .gamma.; interleukins (IL-1, IL-2), GM-CSF and TNF) (Bukowski et al., 1998; Davidson et al., 1998; Hellstrand et al., 1998) gene therapy (e.g., TNF, IL-1, IL-2, p53) (Qin et al., 1998; Austin-Ward and Villaseca, 1998; U.S. Pat. Nos. 5,830,880 and 5,846,945) and monoclonal antibodies (e.g., anti-ganglioside GM2, anti-HER-2, anti-p185) (Pietras et al., 1998; Hanibuchi et al., 1998; U.S. Pat. No. 5,824,311). Herceptin (trastuzumab) is a chimeric (mouse-human) monoclonal antibody that blocks the HER2-neu receptor. It possesses anti-tumor activity and has been approved for use in the treatment of malignant tumors (Dillman, 1999). Combination therapy of cancer with herceptin and chemotherapy has been shown to be more effective than the individual therapies. Thus, it is contemplated that one or more anti-cancer therapies may be employed with the combination therapy described herein.
[0066] Other immunotherapies contemplated for use in methods of the present disclosure include those described by Tchekmedyian et al., 2015, incorporated herein by reference. The immunotherapy may comprise suppression of T regulatory cells (Tregs), myeloid derived suppressor cells (MDSCs) and cancer associated fibroblasts (CAFs). In some embodiments, the immunotherapy is a tumor vaccine (e.g., whole tumor cell vaccines, peptides, and recombinant tumor associated antigen vaccines), or adoptive cellular therapies (ACT) (e.g., T cells, natural killer cells, TILs, and LAK cells). The T cells may be engineered with chimeric antigenreceptors (CARs) or T cell receptors (TCRs) to specific tumor antigens. As used herein, a chimeric antigen receptor (or CAR) may refer to any engineered receptor specific for an antigen of interest that, when expressed in a T cell, confers the specificity of the CAR onto the T cell. Once created using standard molecular techniques, a T cell expressing a chimeric antigen receptor may be introduced into a patient, as with a technique such as adoptive cell transfer. In some aspects, the T cells are activated CD4 and / or CD8 T cells in the individual which are characterized by I FNy "producing CD4 and / or CD8 T cells and / or enhanced cytolytic activity relative to prior to the administration of the combination. The CD4 and / or CD8 T cells may exhibit increased release of cytokines selected from the group consisting of IFN-y, TNF-o and interleukins. The CD4 and / or CD8 T cells can be effector memory T cells. In certain embodiments, the CD4 and / or CD8 effector memory T cells are characterized by having the expression of CD44h'9hCD62|OW.
[0067] Examples of monoclonal antibodies include, but are not limited to, trastuzumab (anti-HER2 / neu antibody); Pertuzumab (anti-HER2 mAb); cetuximab (chimeric monoclonal antibody to epidermal growth factor receptor EGFR); panitumumab (anti-EGFR antibody); nimotuzumab (anti-EGFR antibody); Zalutumumab (anti-EGFR mAb); Necitumumab (anti-EGFR mAb); MDX-210 (humanized anti-HER-2 bispecific antibody); MDX-210 (humanized anti-HER-2 bispecific antibody); MDX-447 (humanized anti-EGF receptor bispecific antibody); Rituximab (chimeric murine / human anti-CD20 mAb); Obinutuzumab (anti-CD20 mAb); Ofatumumab (anti-CD20 mAb); Tositumumab-1131 (anti-CD20 mAb); Ibritumomab tiuxetan (anti-CD20 mAb); Bevacizumab (anti-VEGF mAb); Ramucirumab (anti-VEGFR2 mAb); Ranibizumab (anti-VEGF mAb); Aflibercept (extracellular domains of VEGFR1 and VEGFR2 fused to lgG1 Fc); AMG386 (angiopoietin-1 and -2 binding peptide fused to lgG1 Fc); Dalotuzumab (anti-IGF-1 R mAb); Gemtuzumab ozogamicin (anti-CD33 mAb); Alemtuzumab (anti-Campath-1 / CD52 mAb); Brentuximab vedotin (anti-CD30 mAb); Catumaxomab (bispecific mAb that targets epithelial cell adhesion molecule and CD3); Naptumomab (anti-5T4 mAb); Girentuximab (anti-Carbonic anhydrase ix); or Farletuzumab (anti-folate receptor). Other examples include antibodies such as Panorex.TM. (17-1 A) (murine monoclonal antibody); Panorex (@ (17-1 A) (chimeric murine monoclonal antibody); BEC2 (ami-idiotypic mAb, mimics the GD epitope) (with BCG); Oncolym (Lym-1 monoclonal antibody); SMART M195 Ab, humanized 13' 1 LYM-1 (Oncolym), Ovarex (B43.13, anti-idiotypic mouse mAb); 3622W94 mAb that binds to EGP40 (17-1 A) pancarcinoma antigen on adenocarcinomas; Zenapax (SMART Anti-Tac (IL-2 receptor); SMART M195 Ab, humanized Ab, humanized); NovoMAb-G2 (pancarcinoma specific Ab); TNT (chimeric mAb to histone antigens); TNT (chimeric mAb to histone antigens); Gliomab-H (Monoclonals-Humanized Abs); GNI-250 Mab; EMD-72000 (chimeric-EGF antagonist); LymphoCide (humanized IL.L.2 antibody); and MDX-260 bispecific, targets GD-2, ANA Ab, SMART IDIO Ab, SMART ABL 364 Ab or ImmuRAIT-CEA. Examples of antibodies include those disclosed in U.S. Pat. Nos. 5,736,167, 7,060,808, and 5,821,337.
[0068] Further examples of antibodies include anti-human 0X40 agonist antibody (Genentech);Zanulimumab (anti-CD4 mAb), Keliximab (anti-CD4 mAb); Ipilimumab (MDX-101; anti-CTLA-4 mAb);Tremilimumab (anti-CTLA-4 mAb); (Daclizumab (anti-CD25 / IL-2R mAb); Basiliximab (anti-CD25 / IL-2R mAb); MDX-1106 (anti-PD1 mAb); antibody to GITR; GC1008 (anti-TGF-.beta. antibody); metelimumab / CAT-192 (anti-TGF-.beta. antibody); lerdelimumab / CAT-152 (anti-TGF-.beta. antibody); ID11 (anti-TGF-.beta. antibody);Denosumab (anti-RANKL mAb); BMS-663513 (humanized anti-4-1 BB mAb); SGN-40 (humanized anti-CD40 mAb); CP870,893 (human anti-CD40 mAb); Infliximab (chimeric anti-TNF mAb; Adalimumab (human anti-TNF mAb); Certolizumab (humanized Fab anti-TNF); Golimumab (anti-TNF); Etanercept (Extracellular domain of TNFR fused to lgG1 Fc); Belatacept (Extracellular domain of CTLA-4 fused to Fc); Abatacept (Extracellular domain of CTLA-4 fused to Fc); Belimumab (anti-B Lymphocyte stimulator); Muromonab-CD3 (anti-CD3 mAb); Otelixizumab (anti-CD3 mAb); Teplizumab (anti-CD3 mAb); Tocilizumab (anti-IL6R mAb); REGN88 (anti-IL6R mAb); Ustekinumab (anti-IL-12 / 23 mAb); Briakinumab (anti-IL-12 / 23 mAb); Natalizumab (anti-.alpha.4 integrin); Vedolizumab (anti-.alpha.4 .beta.7 integrin mAb); T1 h (anti-CD6 mAb); Epratuzumab (anti-CD22 mAb);Efalizumab (anti-CD11 a mAb); and Atacicept (extracellular domain of transmembrane activator and calcium-modulating ligand interactor fused with Fc).
[0069] It is contemplated that other agents may be used in combination with the compositions provided herein to improve the therapeutic efficacy of treatment. These additional agents include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, or agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers. Immunomodulatory agents include tumor necrosis factor; interferon alpha, beta, and gamma; IL-2 and other cytokines; F42K and other cytokine analogs; or MIP-1, MIP-1beta, MCP-1, RANTES, and other chemokines. It is further contemplated that the upregulation of cell surface receptors or their ligands such as Fas / Fas ligand, DR4 or DR5 / TRAIL would potentiate the apoptotic inducing abilities of the compositions provided herein by establishment of an autocrine or paracrine effect on hyperproliferative cells. Increases intercellular signaling by elevating the number of GAP junctions would increase the anti-hyperprol iterative effects on the neighboring hyperproliferative cell population. In other embodiments, cytostatic or differentiation agents can be used in combination with the compositions provided herein to improve the anti-hyerproliferative efficacy of the treatments. Inhibitors of cell adhesion are contemplated to improve the efficacy of the present invention. Examples of cell adhesion inhibitors are focal adhesion kinase (FAKs) inhibitors and Lovastatin. It is further contemplated that other agents that increase the sensitivity of a hyperproliferative cell to apoptosis, such as the antibody c225, could be used in combination with the compositions provided herein to improve the treatment efficacy.
[0070] In some embodiments, cancer therapy comprises the use of one or more oncolytic viruses. Examples of oncolytic viruses include adenoviruses, adeno-associated viruses, retroviruses, lentiviruses, herpesviruses, pox viruses, vaccinia viruses, vesicular stomatitis viruses, polio viruses, Newcastle's Disease viruses, Epstein-Barr viruses, influenza viruses and reoviruses. In a particular embodiment, the other agent is talimogene laherparepvec (T-VEC) which is an oncolytic herpes simplex virus genetically engineered to express GM-CSF. Talimogene laherparepvec, HSV-1 [strain JS1] ICP34.5- / ICP47- / hGM-CSF, (previously known as OncoVEX.sup.GM CSF) is an intratumorally delivered oncolytic immunotherapy comprising an immune-enhanced HSV-1 that selectively replicates in solid tumors. (Lui et al., 2003; U.S. Pat. Nos. 7,223,593 and 7,537,924; incorporated herein by reference).
[0071] In some embodiments, hormonal therapy may also be used in conjunction with the in combination with any other cancer therapy previously described. The use of hormones may be employed in the treatment of certain cancers such as breast, prostate, ovarian, or cervical cancer to lower the level or block the effects of certain hormones such as testosterone or estrogen. This treatment is often used in combination with at least one other cancer therapy as a treatment option or to reduce the risk of metastases.
[0072] In some aspects, cancer therapy comprises the use of a protein kinase inhibitor or a monoclonal antibody that inhibits receptors involved in protein kinase or growth factor signaling pathways such as an EGFR, VEGFR, AKT, Erb1, Erb2, ErbB, Syk, Bcr-Abl, JAK, Src, GSK-3, PI3K, Ras, Raf, MAPK, MAPKK, mTOR, c-Kit, eph receptor or BRAF inhibitors. Nonlimiting examples of protein kinase or growth factor signaling pathways inhibitors include Afatinib, Axitinib, Bevacizumab, Bosutinib, Cetuximab, Crizotinib, Dasatinib, Erlotinib, Fostamatinib, Gefitinib, Imatinib, Lapatinib, Lenvatinib, Mubritinib, Nilotinib, Panitumumab, Pazopanib, Pegaptanib, Ranibizumab, Ruxolitinib, Saracatinib, Sorafenib, Sunitinib, Trastuzumab, Vandetanib, AP23451, Vemurafenib, MK-2206, GSK690693, A-443654, VQD-002, Miltefosine, Perifosine, CAL101, PX-866, LY294002, rapamycin, temsirolimus, everolimus, ridaforolimus, Alvocidib, Genistein, Selumetinib, AZD-6244, Vatalanib, P1446A-05, AG-024322, ZD1839, P276-00, GW572016 or a mixture thereof.
[0073] In some aspects, the PI3K inhibitor is selected from the group of PI3K inhibitors consisting of buparlisib, idelalisib, BYL-719, dactolisib, PF-05212384, pictilisib, copanlisib, copanlisib dihydrochloride, ZSTK-474, GSK-2636771 , duvelisib, GS-9820, PF-04691502, SAR-245408, SAR-245409, sonolisib, Archexin, GDC-0032, GDC-0980, apitolisib, pilaralisib, DLBS 1425, PX-866, voxtalisib, AZD-8186, BGT-226, DS-7423, GDC-0084, GSK-21 26458, INK-1 1 17, SAR-260301, SF-1 1 26, AMG-319, BAY-1082439, CH-51 32799, GSK-2269557, P-71 70, PWT-33597, CAL-263, RG-7603, LY-3023414, RP-5264, RV-1729, taselisib, TGR-1 202, GSK-418, INCB-040093, Panulisib, GSK-105961 5, CNX-1351, AMG-51 1, PQR-309, 17beta-Hydroxywortmannin, AEZS-129, AEZS-136, HM-5016699, IPI-443, CNC-201, PF-4989216, RP-6503, SF-2626, X-339, XL-499, PQR-401, AEZS-132, CZC-24832, KAR-4141, PQR-31 1, PQR-316, RP-5090, VS-5584, X-480, AEZS-126, AS-604850, BAG-956, CAL-130, CZC-24758, ETP-46321, ETP-471 87, GNE-317, GS-548202, HM-032, KAR-1 139, LY-294002, PF-04979064, PI-620, PKI-402, PWT-143, RP-6530, 3-HCI-BA-01, AEZS-134, AS-041 164, AS-252424, AS-605240, AS-605858, AS-606839, BCCA-621 C, CAY-10505, CH-5033855, CH-51 08134, CUDC-908, CZC-1 9945, D-106669, D-87503, DPT-NX7, ETP-46444, ETP-46992, GE-21, GNE-123, GNE-151, GNE-293, GNE-380, GNE-390, GNE-477, GNE-490, GNE-493, GNE-614, HMPL-51 8, HS-104, HS-1 06, HS-1 16, HS-173, HS-196, IC-486068, INK-055, KAR 1 141, KY-1 2420, Wortmannin, Lin-05, NPT-520-34, PF-04691503, PF-06465603, PGNX-01, PGNX-02, PI 620, PI-103, PI-509, PI-516, PI-540, PIK-75, PWT-458, RO-2492, RP-5152, RP-5237, SB-201 5, SB-2312, SB-2343, SHBM-1009, SN 32976, SR-13179, SRX-2523, SRX-2558, SRX-2626, SRX-3636, SRX-5000, TGR-5237, TGX-221, UCB-5857, WAY-266175, WAY-266176, El-201, AEZS-131, AQX-MN100, KCC-TGX, OXY-1 1 1 A, PI-708, PX-2000, and WJD-008.
[0074] It is contemplated that the cancer therapy can comprise an antibody, peptide, polypeptide, small molecule inhibitor, siRNA, miRNA or gene therapy which targets, for example, epidermal growth factor receptor (EGFR, EGFR1, ErbB-1, HER1), ErbB-2 (HER2 / neu), ErbB-3 / HER3, ErbB-4 / HER4, EGFR ligand family; insulinlike growth factor receptor (IGFR) family, IGF-binding proteins (IGFBPs), IGFR ligand family (IGF-1R); platelet derived growth factor receptor (PDGFR) family, PDGFR ligand family; fibroblast growth factor receptor (FGFR) family, FGFR ligand family, vascular endothelial growth factor receptor (VEGFR) family, VEGF family; HGF receptor family: TRK receptor family; ephrin (EPH) receptor family; AXL receptor family; leukocyte tyrosine kinase (LTK) receptor family; TIE receptor family, angiopoietin 1, 2; receptor tyrosine kinase-like orphan receptor (ROR) receptor family; discoidin domain receptor (DDR) family; RET receptor family; KLG receptor family; RYK receptor family; MuSK receptor family; Transforming growth factor alpha (TGF-o), TGF-o receptor; Transforming growth factor-beta (TGF-.beta.), TGF-.beta. receptor; Interleukin 13 receptor alpha2 chain (1 L13Ralpha2), lnterleukin-6 (IL-6), 1L-6 receptor, lnterleukin-4, IL-4 receptor, Cytokine receptors, Class I (hematopoietin family) and Class II (interferon / 1 L-10 family) receptors, tumor necrosis factor (TNF) family, TNF-o, tumor necrosis factor (TNF) receptor superfamily (TNTRSF), death receptor family, TRAIL-receptor; cancer-testis (CT) antigens, lineage-specific antigens, differentiation antigens, alpha-actinin-4, ARTC1, breakpoint cluster region-Abelson (Bcr-abl) fusion products, B-RAF, caspase-5 (CASP-5), caspase-8 (CASP-8), beta-catenin (CTNNB1), cell division cycle 27 (CDC27), cyclin-dependent kinase 4 (CDK4), CDKN2A, COA-1, dek-can fusion protein, EFTUD-2, Elongation factor 2 (ELF2), Ets variant gene 6 / acute myeloid leukemia 1 gene ETS (ETC6-AML1) fusion protein, fibronectin (FN), GPNMB, low density lipid receptor / GDP-L fucose: beta-Dgalactose 2-alpha-Lfucosyltraosferase (LDLR / FUT) fusion protein, HLA-A2, arginine to isoleucine exchange at residue 170 of the alpha-helix of the alpha2-domain in the HLA-A2 gene (HLA-A*201-R1700, MLA-A11, heat shock protein 70-2 mutated (HSP70-2M), KIAA0205, MART2, melanoma ubiquitous mutated 1, 2, 3 (MUM-1, 2, 3), prostatic acid phosphatase (PAP), neo-PAP, Myosin class 1, NFYC, OGT, OS-9, pml-RARalpha fusion protein, PRDXS, PTPRK, K-ras (KRAS2), N-ras (NRAS), HRAS, RBAF600, SIRT2, SNRPD1, SYT-SSX1 or -SSX2 fusion protein, Triosephosphate Isomerase, BAGE, BAGE-1, BAGE-2,3,4,5, GAGE-1,2,3,4,5,6,7,8, GnT-V (aberrant N-acetyl giucosaminyl transferase V, MGATS), HERV-K-MEL, KK-LC, LAGE, LAGE-1, CTL-recognixed antigen on melanoma (CAMEL), MAGE-A1 (MAGE-1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-AS, MAGE-A6, MAGE-A8, MAGE-A9, MAGE-A10, MAGE-A11, MAGE-A12, MAGE-3, MAGE-B1, MAGE-B2, MAGE-B5, MAGE-B6, MAGECI, MAGE-C2, mucin 1 (MUC1), MART-1 / Melan-A (MLANA), gp100, gp100 / Pme117 (S1LV), tyrosinase (TYR), TRP-1, HAGE, NA-88, NY-ESO-1, NY-ESO-1 / LAGE-2, SAGE, Sp17, SSX-1,2,3,4, TRP2-1NT2, carcino-embryonic antigen (CEA), Kallikfein 4, mammaglobm-A, OA1, prostate specific antigen (PSA), prostate specific membrane antigen, TRP-1 / gp75, TRP-2, adipophilin, interferon inducible protein absent in nielanorna 2 (AIM-2), BING-4, CPSF, cyclin D1, epithelial cell adhesion molecule (Ep-CAM), EpbA3, fibroblast growth factor-5 (FGF-5), glycoprotein 250 (gp250intestinal carboxyl esterase (iCE), alpha-feto protein (AFP), M-CSF, mdm-2, MUCI, p53 (TP53), PBF, FRAME, PSMA, RAGE-1, RNF43, RU2AS, SCX10, STEAP1, survivin (BIRCS), human telomerase reverse transcriptase (hTERT), telomerase, Wilms' tumor gene (WT1), SYCP1, BRDT, SPANX, XAGE, ADAM2, PAGE-5, LIP1, CTAGE-1, CSAGE, MMA1, CAGE, BORIS, HOM-TES-85, AF15q14, HCA66I, LDHC, MORC,SGY-1 , SP011, TPX1, NY-SAR-35, FTHLI7, NXF2 TDRD1, TEX 15, FATE, TPTE, immunoglobulin idiotypes, Bence-Jones protein, estrogen receptors (ER), androgen receptors (AR), CD40, CD30, CD20, CD19, CD33, CD4, CD25, CD3, cancer antigen 72-4 (CA 72-4), cancer antigen 15-3 (CA 15-3), cancer antigen 27-29 (CA 27-29), cancer antigen 125 (CA 125), cancer antigen 19-9 (CA 19-9), beta-human chorionic gonadotropin, 1-2 microglobulin, squamous cell carcinoma antigen, neuron-specific enoJase, heat shock protein gp96, GM2, sargramostim, CTLA-4, 707 alanine proline (707-AP), adenocarcinoma antigen recognized by T cells 4 (ART-4), carcinoembryogenic antigen peptide-1 (CAP-1), calcium-activated chloride channel-2 (CLCA2), cyclophilin B (Cyp-B), human signet ring tumor-2 (HST-2), Human papilloma virus (HPV) proteins (HPV-E6, HPV-E7, major or minor capsid antigens, others), Epstein-Barr vims (EBV) proteins (EBV latent membrane proteins-LMP1, LMP2; others), Hepatitis B or C virus proteins, and HIV proteins.
[0075] In some embodiments, the cancer therapy comprises the use of checkpoint inhibitor. In some embodiments, the checkpoint inhibitor is a small molecule, an inhibitory nucleic acid, an inhibitory polypeptide, antibody or antigen-binding domain thereof, or antibody reagent. In some embodiments, the checkpoint inhibitor is an antibody or antigen-binding domain thereof, or antibody reagent binds an immune checkpoint polypeptide and inhibits its activity. Common checkpoints that are targeted for therapeutics include, but are not limited to PD-L1, PD-L2, PD-1, CTLA-4, TIM-3, LAG-3, VISTA, and TIGIT. In some embodiments, the checkpoint inhibitor is an antibody or antigen-binding domain thereof, or antibody reagent binds a PD-1, PD-L1, or PD-L2 polypeptide and inhibits its activity.
[0076] Inhibitors of known checkpoint regulators (e.g., PD-L1, PD-L2, PD-1, CTLA-4, TIM-3, LAG-3, VISTA, or TIGIT) are known in the art. Non-limiting examples of checkpoint inhibitors (with checkpoint targets and manufacturers noted in parentheses) can include: MGA271 (B7-H3: MacroGenics); ipilimumab (CTLA-4; Bristol Meyers Squibb); pembrolizumab (PD-1; Merck); nivolumab (PD-1; Bristol Meyers Squibb); atezolizumab (PD-L1; Genentech); IMP321 (LAG3: Immuntep); BMS-986016 (LAG3; Bristol Meyers Squibb); IPH2101 (KIR; Innate Pharma); tremelimumab (CTLA-4; Medimmune); pidilizumab (PD-1; Medivation); MPDL3280A (PD-L1; Roche); MEDI4736 (PD-L1; AstraZeneca); MSB0010718C (PD-L1; EMD Serono); AUNP12 (PD-1; Aurigene); avelumab (PD-L1; Merck); durvalumab (PD-L1; Medimmune); and TSR-022 (TIM3; Tesaro).
[0077] In some embodiments, the checkpoint inhibitor inhibits PD-1. PD-1 inhibitors include, but are not limited to Pembrolizumab (Keytruda™), Nivolumab, AUNP-12, and Pidilizumab. In another embodiment, the checkpoint inhibitor inhibits PD-L1. PD-L1 inhibitors include, but are not limited to Atezolizumab, MPDL3280A, Avelumab, and Durvalumab.
[0078] In some embodiments, the cancer therapy comprises surgical intervention to remove cancerous tissue. In some embodiments, the cancer is bladder cancer and the surgical intervention comprises a full cystectomy and / or transurethral resection of bladder tumor (TURBT).
[0079] It is contemplated that the methods herein reduce tumor burden, and / or reduce metastasis in the subject, and / or reduce or prevent the recurrence of tumors once the cancer has gone into remission. In variousembodiments, the methods reduce the tumor size by 10%, 20%, 30% or more. In various embodiments, the methods reduce tumor size by 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0080] Monitoring efficacy of cancer therapy is also contemplated. In this regard, the disclosure provides a method of monitoring efficacy of treatment in a subject undergoing cancer therapy comprising detecting a level of hyaluronidase 2-positive myeloid cells in a blood sample from the subject before and after treatment with a cancer therapy, wherein a decreased level of hyaluronidase 2-positive myeloid cells identified in the blood sample after cancer therapy compared to before treatment began is indicative of effective treatment. A decreased level of hyaluronidase 2-positive myeloid cells (such that the level of hyaluronidase 2-positive myeloid cells in the sample is commensurate with a level of hyaluronidase 2-positive myeloid cells in healthy subjects) in the sample is indicative of effective cancer therapy.
[0081] All of the references cited herein, including patents, patent applications, literature publications, and the like, are hereby incorporated in their entireties by reference.EXAMPLES
[0082] Materials and Methods
[0083] Reagents and culture media. The fluorochrome-labeled antibodies against PD-L1, CD11b, F4 / 80, CD8, and CD31 were acquired from BioLegend (San Diego, CA). The anti-mouse PD1 (clone RMP1-14), CTLA-4 (clone 9H10) blocking antibodies, and control IgG antibodies for in vivo experiments were purchased from BioXCell (Lebanon, NH). In vitro experiments were conducted using RPM1 1640 medium (Corning), supplemented with 20 mM HEPES, 200 U / ml penicillin, 50 pg / ml streptomycin (all from Hyclone), and 10% FBS from American Type Culture Collection (Manassas, VA).
[0084] Mice and tumor models. Female 6- to 8-week-old C3 / He and C57 / BL6 mice were obtained from the Envigo and NOD-SCID mice from Charles River. The murine bladder carcinoma cell line MBT2 was purchased from JCRB Cell Bank (Japan), murine bladder tumor cell line MB49, and human bladder cancer cell lines SW780, Scaber from ATCC (Manassas, VA). Tumor cells were maintained at 37°C in a 5% CO2 humidified atmosphere in complete culture media.
[0085] Cell isolation. MBT2 tumors were collected from tumor-bearing mice on day 14 after subcutaneous tumor injection. Single-cell tumor suspension was prepared using mechanical and enzymatic digestion as described. CD11b+ myeloid cells were isolated from the MBT2 tumor cell suspension using MACS columns (Miltenyi Biotec, Auburn, CA). Briefly, the tumor cell suspension was incubated with anti-FcR blocking antibodies and then anti-CD11b microbeads according to manufacturer's protocol. After washing with cold MACS buffer tumor cell suspension was subsequently subjected to a positive selection of CD11b cells on MACS LS columns.
[0086] Preparation of organotypic tumor tissue slices. The precision-cut 300-pm tissue slices were prepared with Compresstome tissue slicer VF-300-0Z using freshly collected human cancer tissue or mouse tumors (25).Immediately after tissue cutting, slices were placed into 24-well cell culture plates in complete RPM 1-1640 medium supplemented with 10% FBS and antibiotics and cultured in a humidified CO2 incubator for 3-14 days. Cell viability of cultured tissue slices was tested using the Live / Dead kit (Invitrogen).
[0087] Preparation ofHyal2-PNU ADC. The anti-Hyal2 monoclonal antibodies of mouse origin (comprising the CDRs set forth in SEQ ID NOs: 2-7), which recognize both mouse and human membrane bound enzyme Hyal2 were utilized for the ADC preparation. As a payload for ADC preparation, the anthracycline drug metabolite PNU was used, which has been successfully used in several recent studies (27-29). Hyal2-ADC and control ADC were prepared using a commercial kit from Genovis AB. A mouse IgG conjugated with PNU (IgG-ADC) was used as a negative target-nonspecific control. ADCs were prepared according to the manufacturer's instructions.
[0088] MTT assay. Murine MBT-2 and human SW780 bladder cancer cell lines were seeded in 96-well microplates at a density of 1 x 104cells / well with 100 pl of culture media per well, and then treated with serial concentrations of Hyal2-PNU ADC (antibody) or control IgG-PNU ADC (IgG) for 96 hours (n = 4). Cell viability was then assessed using a thiazolyl blue tetrazolium bromide following the manufacturer's protocol. The signals were measured with a UV / vis microplate spectrophotometer (BioTek). Percent cell viability was calculated as (test CD570 / nontreated CD570) x 100%. The IC 50 was calculated by fitting data to nonlinear regression with GraphPad Prism 5 software.
[0089] In vivo treatment. To establish subcutaneous tumors, we injected mice with 5 x 105tumor cells into the right flank of syngeneic mice (C3 / H mice for MBT2 tumor, and C57 / BL6 for MB49 tumor), according to our approved IACUC protocol (University of Florida, Gainesville). To evaluate the effects of Hyal2-ADC on tumor growth mice with established, palpable tumors were grouped and received one of the following treatments: Group 1: Control IgG-ADC (i.v); Group 2: anti-PD1 or anti-CTLA-4 monotherapy (i.p.); Group 3: Hyal2-ADC monotherapy (i.v.); Group 4: Combo (Hyal2-ADC and immune checkpoint inhibitor). The following doses of ADC were used in these in vivo studies: 35 pig / mouse (1.75 mg / kg); 50 pig / mouse (2.5 mg / kg), 70 pig / mouse (3.5 mg / kg), and 100 pig / mouse (5 mg / kg), The tumor size was measured every 3 days using a Vernier caliper. The number and percentage of surviving mice in each group were plotted against time using the Kaplan-Meier method.
[0090] Human studies. Tumor tissues from 12 patients diagnosed with bladder urothelial carcinomas were collected during transurethral resection of a bladder tumor or radical cystectomy at the Department of Urology, University of Florida. Surgically removed tumor tissues were obtained from patients with bladder cancer after informed consent and approval by the University of Florida Institutional Review Board (IRB).
[0091] Immunohistochemistry. Formalin-fixed paraffin-embedded (FFPE) blocks of human tissues were processed by Molecular Pathology Core at the University of Florida, Gainesville. 4-pm sections from FFPE tissue blocks were deparaffinized in xylene (Sigma-Aldrich), and rehydrated by sequential incubation in 100%, 95%, and 70% ethanol and DI water. Antigen retrieval was performed by heating slides in citrate buffer (Vector Laboratories) according to the manufacturer's instructions. Following treatment with 3% hydrogen peroxide,blocking solution (Abeam), the tissue slides were incubated with primary anti-Hyal2, anti-PD-L1 , and anti-CD31 antibodies overnight at 40C. Staining with secondary antibodies (Akoya Biosciences) was performed according to the manufacturer's protocol. Stained tissue slides were mounted using VectaMount (Vector Laboratories) and observed using an EVOS fluorescent imaging microscope (Life Technology) or Lionheart (BioTek Instruments).
[0092] Western Blotting. Cells were lysed in mammalian protein extraction reagent (M-PER) (Thermo Scientific) containing protease and phosphatase inhibitors. Whole-cell lysates (30 pig per lane) were subjected to 10% SDS / PAGE and blotted onto PVDF membranes. Membranes were blocked for one hour at room temperature with 5% skimmed milk in TBST (20 mM Tris-HCI (pH 7.6), 137 NaCI 0.1% (vol / vol) Tween 20) and probed with appropriate primary Abs overnight at 4°C. Membranes were washed and incubated for 1h at room temperature with secondary antibody conjugated with HRP. Results were visualized by chemiluminescence detection using a SuperSignal West Pico substrate (Thermo Scientific).
[0093] Statistical analysis. The Student's t-test was utilized to determine the statistical significance between values. All data were expressed as the mean ± SD. The p values >0.05 were considered nonsignificant.Significant p values <0.05 were expressed with an asterisk (*). For in vivo studies, the number and percentage of surviving mice in each group were plotted against time using the Kaplan-Meier method (Prizm GraphPad). Statistical analysis of Kaplan-Myers survival plots was conducted using the Mantel-Cox long-rank test.Example 1 - Both tumor-associated myeloid cells and bladder cancer epithelial cells express Hyal2
[0094] The accumulation of hyaluronidase 2 (Hyal2)-expressing tumor-infiltrating myeloid cells has been detected in both cancer patients and animals with experimental tumors (17, 24, 25). These cells contribute to the cancer-associated ECM remodeling through the degradation of extracellular HA, mediated by membrane-bound enzyme Hyal2. In addition to Hyal2, these cells co-express the immunosuppressive ligand PD-L1 (FIG. 1 A and FIG. 1 B). Single-cell RNA sequencing confirmed the expression of PD-L1 by Hyal2-positive myeloid cells (FIG.1 C). Thus, the Hyal2+CD11b+ myeloid-derived suppressor cells (MDSCs) were isolated from the spleens of mice bearing syngeneic MBT2 bladder tumors. To define the transcriptional signature of Hyal2+ MDSCs, a scRNAseq library was subsequently sequenced on an Illumina NovaSeq sequencer. After initial quality control, 12,000 cells were clustered based on the most differentially expressed genes and visualized using uniform manifold approximation and projection. Eight distinct Hyal2+ cell subsets were identified. Clusters depict various transcriptional programs that reflect the differentiation and activation stages of Hyal2+ myeloid cells. Cluster 5 was enriched for several up-regulated genes associated with immunosuppressive and inflammatory functions including CD274 (PD-L1), CCL3, TANK (TRAF family member-associated NF-kappa-B activator), dusp2, MALT1 and others. These data support the finding that Hyal2+ myeloid cells co-express immunosuppressive ligand PD-L1. Collectively, the data provided herein suggests that in addition to ECM remodeling via membrane-bound enzyme Hyal2, these cells also contribute to tumor-associated immune suppression.Example 2 - In vitro targeting of Hyal2 with antibody-drug conjugate inhibits the proliferation of tumor cells and prevents the development of tumor-associated PD-L1 macrophages
[0095] To prepare anti-Hyal2 ADC (Hyal2-ADC), anti-Hyal2 antibodies were conjugated with the cytotoxic payload PNU (27-29). To evaluate the anti-tumor activity of prepared Hyal2-ADC in vitro, the MTT assay was utilized. Briefly, Hyal2-ADC or control IgG-ADC conjugates were added to the cultures of mouse MBT2 or human SW780 tumor cells on Day 0 at indicated doses. Specific binding of Hyal2-ADC to tumor cells was confirmed by immunofluorescent analysis (data not shown). Data presented in FIG. 1 E demonstrate that Hyal2-ADC exerts strong dose-dependent inhibition of proliferation of both mouse (MBT2) and human (SW780) bladder cancer cells.
[0096] Since Hyal2+ myeloid cells co-express PD-L1, whether the elimination of Hyal2-expressing cells with Hyal2-ADC could reduce the number of immunosuppressive PD-L1 + myeloid cells was tested. The differentiation of MDSCs into PD-L1+F4 / 80+ macrophages could be induced in vitro by exposure of Gr-1+ MDSCs to tumor-conditioned medium (TOM) (26). To evaluate the effect of Hyal2-ADC on the development of MDSC-derived PD-L1 + macrophages, we co-cultured the bone marrow-derived myeloid cells with TOM in the presence of control IgG-ADC or Hyal2-ADC for six days. Data presented in FIG..2A and FIG. 2B indicate that the addition of Hyal2-ADC efficiently reduced the numbers of PD-L1+F4 / 80+ macrophages that developed in vitro in the presence of TCM.
[0097] The effect of Hyal2-ADC on forming PD-L1 + macrophages ex vivo, in the tumor microenvironment was examined using organotypic tumor tissue slice cultures (30-32). This method establishes organoid-like tissue cultures directly from resected tumor tissue, requiring minimal tissue processing while preserving the histologic growth patterns, ECM, and infiltrating immune cells. To this end, we prepared the tissue slice cultures using murine MBT2 bladder tumors. Either IgG-ADC or Hyal2-ADC (250 ng / ml) was added to the tissue cultures immediately after tissue cutting the tumor slices. Five days later, cultures were fixed with 4% formaldehyde and stained for PD-L1 and DAPI. Data presented in FIG. 2C and FIG. 2D show that the addition of Hyal2-ADC significantly reduced the number of PD-L1 -positive cells in tumor tissue slice cultures as compared to control.Example 3 - Administration of Hyal2-ADC in mice with established tumors results in a dose-dependent inhibition of tumor growth
[0098] To examine the potential therapeutic anti-tumor effect of Hyal2-ADC, the Hyal2-ADC was injected in mice with established syngeneic murine MBT2 tumors. Data presented in FIG 3A and FIG 3B demonstrate that systemic intravenous injection of Hyal2-ADC led to dose-dependent inhibition of tumor growth. Thus, two consecutive injections with a low dose (35 pig / mouse) resulted in slowing of tumor growth. However, several days after the second injection, tumor growth accelerated. Administration of 70 pig / mouse Hyal2-ADC led to complete tumor regression in 1 out of 5 treated mice (20 %), whereas Hyal2-ADC monotherapy with 100 pig / mouse eliminated 2 out of 5 established MBT2 tumors (40%). Notably, the non-targeted control IgG-ADC conjugate did not show any anti-tumor activity.
[0099] To evaluate the effects of Hyal2-ADC on tumor-infiltrating PD-L1 + cells, a single dose of Hyal2-ADC or control IgG-ADC (70 pig / mouse) was injected into mice with established, palpable MBT2 tumors. On day 6after intravenous injection of ADC, tumors were excised and processed to prepare the single-cell suspension. The tumor cell suspension was stained and analyzed for the presence of PD-L1 + macrophages. As shown in FIG. 7, tumor tissue in mice treated with Hyal2-ADC contained a significantly lower number of immunosuppressive PD-L1 + cells.
[0100] Next, the effects of two different Hyal2 antibodies (i.e., Hyal2A and Hy al2B) in an ADC was evaluated. The Hyal2A antibody comprises the CDRs set forth in SEQ ID NOs: 2-7. The Hy al2B antibody comprises the CDRs set forth in SEQ ID NOs: 12-17. C3 / He mice were inoculated with syngeneic murine bladder MBT2 tumor cells (s.c., 0.5x106cells / mouse). On day 7 when tumors became palpable (6-7 mm in diameter), mice were injected once i.v. with vehicle (PBS), control IgG-PNU conjugates, Hyal2A-PNU ADC or Hyal2B-PNU ADC (100 mg / mouse). As shown in Figures 8A and 8B, Hyal2A-PNU ADC was superior to the Hyal2B-PNU ADC.Example 4 - Combining Hyal2-ADC with checkpoint inhibitors significantly improves the efficacy of cancer immunotherapy
[0101] Next, whether the anti-tumor effect of Hyal2-ADC could be further enhanced by co-administration of anti-PD1 antibodies which protect T cells and preserve their immune function was explored (33). Anti-Hyal2 antibodies comprising the CDRs set forth in SEQ ID NOs: 2-7 were used for the following experiment.
[0102] Mice with established early-stage MBT2 tumors (day 7, tumor size < 200 mm3in volume), received one of the following treatments: Control IgG-ADC, anti-PD1 mAbs alone (200 pig / mouse i.p.), Hyal2-ADC monotherapy (50 pig / mice), or combined treatment with Hyal2-ADC + anti-PD1 mAbs. As shown in FIG. 4A (left panel) and 4B, the Hyal2-ADC monotherapy led to tumor regression in 1 out of 5 of the mice (20%), while the combination treatment resulted in complete regression in all treated mice (5 out of 5, 100%). To examine the therapeutic effect of combination treatment in mice with more advanced tumors, treatment was started on day 10 after tumor inoculation, when tumors reached 200-260 mm3in volume. The dose of Hyal2-ADC was increased to 100 pig / per mouse. Data indicate that injection of 100 pig Hyal2-ADC alone led to tumor regression in 40% of treated mice (2 out of 5). Remarkably, the Hyal2 monotherapy was more efficient than anti-PD 1 monotherapy. The combination treatment (Hyal2-ADC + anti-PD 1 mAbs) cured 80% of treated mice (4 out of 5). The rechallenge of tumor-free mice with tumor cells led to tumor rejection suggesting that these mice developed a protective immunity (data not shown).
[0103] In addition to MBT2 tumor models, the effect of Hyal2-ADC treatment on the growth of another syngeneic murine bladder tumor MB49 was also evaluated. The MB49 tumor is more aggressive with faster growth compared to the MBT2 tumor. Also, in contrast to the MBT2 tumor, the MB49 tumor is more responsive to anti-CTLA-4 than to anti-PD 1 therapy (34). As shown in FIG. 4A (right panel) and FIG. 4B, the monotherapy with anti-CTLA-4 mAbs in mice with established MB49 tumors led to tumor regression in 1 out of 5 mice (20%). The combination of anti-CTLA-4 mAbs with Hyal2-ADC significantly improved the therapeutic effect leading to complete tumor regression in 5 out 5 of the treated mice (100%). Collectively, the experiments described hereindemonstrate that the systemic administration of Hyal2-ADC markedly enhanced the anti-tumor therapeutic efficacy of checkpoint inhibitors such as anti-PD1 and CTLA-4 antibodies.Example 5 - Full immune competence is required for efficient Hyal2-ADC therapy
[0104] Anti-Hyal2 antibodies comprising the CDRs set forth in SEQ ID NOs: 2-7 were used for the following experiment. To take advantage of this antibody's feature, therapeutic efficacy of Hyal2-ADC treatment of advanced human bladder cancer in a preclinical model was assessed. To this end, SW780 human bladder cancer cells were inoculated into immunodeficient NOD-SCID mice. When tumor size reached 200-300 mm3, mice were treated with vehicle control (PBS), control IgG-ADC, or Hyal2-ADC (100 pig / per mouse). Data in FIG.5A indicate that the efficacy of Hyal2-ADC therapy for advanced human bladder cancer (tumors >200 mm3in volume) in immunodeficient NOD-SCID mice is far less effective as compared to syngeneic tumor models in fully immunocompetent mice. The treatment resulted only in a delay of tumor growth, suggesting that complete tumor eradication mediated by anti-Hy al2 therapy requires an intact immune system and the presence of host T lymphocytes.Example 6 - Detection of Hyal2+PD-L1+ cell subset in human bladder cancer
[0105] To examine Hyal2 expression in human bladder cancer, formalin-fixed paraffin-embedded (FFPE) tissue sections were prepared for immunohistochemistry. Using DAB tissue staining (FIG. 5B and FIG.5C), it was determined that Hyal2-positive cells were present in the parenchyma of cancer tissue, and tumor vessels (right panel). Notably, some endothelial cells also expressed Hyal2. Using immunofluorescent staining, both tissueinfiltrating and intra-vessel Hyal2-positive cells co-expressed immunosuppressive ligand PD-L1 (FIG. 5D). Thus, similarly to murine bladder cancer, human bladder cancer is also characterized by the increased presence of Hyal2+PD-L1 + cells. Notably, the elevated numbers of myeloid cells co-expressing PD-L1 and Hyal2 have also been detected in patients with kidney cancer (24).
[0106] It was shown that the peripheral blood of bladder cancer patients is characterized by increased numbers of Hyal2-expressing MDSCs (17). Importantly, in a quiescent resting state, the glycosylphosphatidylinositol (GPI)-linked enzyme Hyal2 is anchored to the plasma membrane and located intracellularly. However, in the presence of inflammatory stimuli such as interleukin 1 beta (IL1B), or upon activation in the tumor microenvironment, Hyal2 translocates to the outer cell membrane and becomes targetable (16). See FIG. 6A. The intracellular localization of Hyal2 in non-activated cells minimizes the potential for off-target effects. Notably, the exposure of blood-derived patient MDSCs to the tumor-conditioned medium (TCM) led to significant upregulation of Hyal2 expression in myeloid cells (FIG. 6B).
[0107] Discussion:
[0108] Previous studies demonstrated that Hyal2 is involved in the remodeling of the ECM in tumors via the degradation of extracellular glycosaminoglycan HA. Increased Hyal2 expression is detected in several cancers including breast, bladder, brain, esophageal squamous cell carcinoma, and possibly in other cancers(14, 15-19, 35, 36). The elevated Hyal2 expression contributes to enhanced HA degradation in tumor tissue, leading to the accumulation of low molecular weight HA fragments (LMW HA), promoting elevated production of tumor-supporting factors including inflammatory cytokines, chemokines, and angiogenic factors in cooperation with TLR2 / TLR4 signaling (20-22). As shown herein, in addition to cancer-related inflammation and tumor angiogenesis, the Hyal2-expressing cells contribute to tumor-associated immune suppression by regulating the anti-tumor T cell response.
[0109] Anti-PD 1 / PD-L1 therapy is one of the most effective approaches for cancer immunotherapy, but the mechanistic basis for this therapy is still not well understood. The binding of the PD1 receptor, which is expressed by T cells, to its ligand PD-L1 inhibits T-cell function in part by suppressing CD28 signaling.Interruption of PD1 / PD-L1 signaling by anti-PD 1 or anti-PD-L1 blocking antibodies preserves T cell function and enhances its anti-tumor immune cytotoxic activity (37). PD-L1 expression is highly predictive of the clinical response to anti-PD 1 therapy (38).
[0110] PD1 is exclusively expressed by T cells, while PD-L1 (CD274, or B7-1 ) can be expressed by cancer epithelial cells or antigen-presenting myeloid cells (APCs) such as dendritic cells (DCs) and macrophages (39-41). It is likely that high PD-L1 expression in cancer cells reflects an epigenetic dysregulation of the PD-L1 gene and is associated with a distinct histology described by poor immune infiltration, sclerotic / desmoplastic stroma, and mesenchymal molecular features (42). There is increased expression of PD-L1 in epithelial cancer cells in metastatic cancers as compared to primary cancers.
[0111] While cancer unresponsiveness to immune checkpoint inhibitors is frequently reported, few studies address the development of novel approaches to overcome the resistance to immunotherapy (1-4). Expression of PD-L1 by host tumor-infiltrating myeloid cell subsets may play a key role in the regulation of the anti-tumor immune response by mediating immune suppression of T cell function through the PD1-PD-L1 axis (43-47). Deep immune profiling, such as spatial tissue analysis at single-cell resolution and mass-spectrometry identified the PD-L1 + tumor-infiltrating myeloid cells as major players in the mechanism of immune evasion and cancer resistance to immunotherapy (44). Furthermore, the expression of the immunosuppressive ligand PD-L1 in tumor-infiltrating myeloid cell subsets (MDSCs, TAMs, DCs) in combination with poor antigen presentation by these cells may represent a more serious obstacle for effective cancer immunotherapy, rather than any intrinsic immunosuppressive properties of tumor cells themselves (43). Overall, these data indicate that PD-L1 + tumorinfiltrating myeloid cell subsets could represent a promising target for therapeutic intervention.
[0112] In this study, two different syngeneic models of murine bladder cancer, MBT2 and MB49 were utilized. The growth of MBT2 tumors is associated with the strong presence of PD-L1+F4 / 80+ macrophages in tumor tissues. The elimination of PD-L1+F4 / 80+ macrophage with anti-Hyal2 ADC significantly improved the therapeutic efficacy of anti-PD 1 antibodies, leading to complete tumor regression of pre-established MBT2 tumors. These data indicate that PD-L1+F4 / 80+TAMs represent a major immunosuppressive component responsible for the resistance of MBT2 tumors to anti-PD 1 immunotherapy.
[0113] Mechanistically, the tumor-recruited Hyal2+ MDSCs of bone marrow origin give rise to PD-L1-expressing TAMs promoting the formation of an immunosuppressive and tolerogenic tumor microenvironment. The membrane-bound enzyme Hyal2 plays a key role in the transition of Hyal2+ MDSCs into highly immunosuppressive TAMs since deletion of the Hyal2 gene in myeloid cells with siRNA significantly reduced the development of PD-L1 -expressing F4 / 80+ macrophages (25). Here, ex vivo targeting with Hyal2-ADC, using organotypic tumor tissue slices was shown to also prevent the formation of PD-L1 + macrophages in the tumor microenvironment. The in vivo targeting of Hyal2 by administration of Hyal2-ADC in immunocompetent syngeneic mice with established tumors resulted in a significant reduction of PD-L1 + cells, as well as in dose-dependent inhibition of tumor growth. Furthermore, co-administration of anti-PD1 mAbs with Hyal2-ADC further improved the anti-tumor immune response, leading to complete regression of established MBT2 tumors. The high therapeutic efficacy of combination treatment (anti-CTLA-4 and Hyal2-ADC) using a different murine bladder tumor model MB49 was confirmed. Collectively, these preclinical studies demonstrate that targeting Hyal2 with ADC could substantially improve the therapeutic efficacy of immune checkpoint inhibitors such as anti-PD 1 and anti-CTLA-4 antibodies.
[0114] SequencesSEQ ID Description SequenceNO:1 Human 1 mragpgptvt lalvlavswa melkptappi ftgrpfvvaw dvptqdcgpr Ikvpldlnaf hyaluronidase61 dvqaspnegf vnqnitifyr drlglyprfd sagrsvhggv pqnvslwahr kmlqkrvehy2121 irtqesagla vidwedwrpv wvrnwqdkdv yrrlsrqlva srhpdwppdr ivkqaqyefe 181 faaqqfmlet Iryvkavrpr hlwgfylfpd cynhdyvqnw esytgrcpdv evarndqlaw241 Iwaestalfp svyldetlas srhgrnfvsf rvqealrvar thhanhalpv yvftrptysr301 rltglsemdl istigesaal gaagvilwgd agyttstetc qylkdyltrl Ivpyvvnvsw361 atqycsraqc hghgrcvrrn psastflhls tnsfrlvpgh apgepqlrpv gelswadidh421 Iqthfrcqcy Igwsgeqcqw dhrqaaggas eawagshlts llalaalaft wtl2 Hyal2A - GYTFTEYAHCDR13 Hyal2A - INPNHGGTHCDR24 Hyal2A - ARDILDYHCDR3Hyal2A - QSLVHSNGDTYLCDR1Hyal2A - KVSLCDR2Hyal2A - SQSTHVPWTLCDR3Hyal2A -VH EVQLQQSGPELVKPGASMKISCKTSGYTFTEYAMFWVKQSHGKSLEWIGGINPNH GGTRYNQKFKGRATLTVDKSSSTAYMELRSLTSEDSAVYYCARDILDYWGQGTTL TVSSHyal2A -VL DWMTQTPLSLPVSLGDRASISCRSSQSLVHSNGDTYLHWYLQKPGQSPKLLIYK VSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLE IKRHyal2A - MGWSWIFLFLLSGTAGVLSEVQLQQSGPELVKPGASMKISCKTSGYTFTEYAMFW Heavy chain, VKQSHGKSLEWIGGINPNHGGTRYNQKFKGRATLTVDKSSSTAYMELRSLTSEDS with signal AVYYCARDILDYWGQGTTLTVSSAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGY FPESVTVTWNSGSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHP ASSTTVDKKLEPSGPISTINPCPPCKECHKCPAPNLEGGPSVFIFPPNIKDVLMISLT PKVTCVWDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTIRWSTLPIQHQ DWMSGKEFKCKVNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCL WGFNPGDISVEWTSNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSF SCNVRHEGLKNYYLKKTISHSPGKHyal2A -Light MKLPVRLLVLMFWIPASSSDWMTQTPLSLPVSLGDRASISCRSSQSLVHSNGDTY chain, with LHWYLQKPGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYF signal CSQSTHVPWTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASWCFLNNFYPK DINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEAT HKTSTSPIVKSFNRNECHy al2B - GYTFTDYTHCDR1Hy al2B - ISTYYGNTHCDR2Hy al2B - AITGTSFAYHCDR315 Hy al2B - QSLLENNGKTYLCDR116 Hy al2B - LVSLCDR217 Hy al2B - WQGTHFPHTLCDR318 Hyal2B -VH QVQLQQSGPELVRPGVSVKISCKGSGYTFTDY TVHWVKQSHAKSLEWI GIISTYYGNTYYNQKF KGKATLTVDKSSYTAY MELARLTSEDSTIYYC AITGTSFAYWGQGTLV TVSA19 Hy al2B - VL DVVMTQTPLTLSVTFGQPASISCKSSQSLLEN NGKTYLNWLLQRPGQS PKRLIYLVSKLDSGVP DRFTGSGSGTDFTLKI SRVEAEDLGVYYCWQG THFPHTFGGGTKLEIKR20 Hyal2C-VH EVQLVQSGSELKKPGASVKVSCKTSGYTFTEYAMFWVKQPPGKGLEWIGGINPNH GGTRYNQKFKGRVTMTVDKSSSTAYMELSSLRSEDTAVYYCARDILDYWGQGTTVT VSS21 Hyal2C-VL DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGDTYLHWYQQKPGQPPKLLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKVEIK22 Hyal2D-VH EVQLVQSGSELKKPGASVKVSCKTSGYTFTEYAMFWVKQPPGKGLEWIGGINPNH GGTRYNQKFKGRVTMTVDKSTSTAYMELSSLRSEDTAVYYCARDILDYWGQGTTV TVSS23 Hyal2D-VL DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGDTYLHWYQQKPGQPPKLLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKVEIK24 Hyal2E-VH EVQLVQSGSELKKPGASVKVSCKTSGYTFTEYAMFWVKQPPGKGLEWIGGINPNH GGTRYNQKFKGRVTMTTDKSTSTAYMELSSLRSEDTAVYYCARDILDYWGQGTTVT VSS25 Hyal2E-VL DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGDTYLHWYQQKPGQPPKLLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKVEIK26 Hyal2F-VH EVQLVQSGSELKKPGASVKVSCKTSGYTFTEYAMFWVKQPHGKGLEWIGGINPNH GGTRYNQKFKGRVTMTVDKSSSTAYMELSSLRSEDTAVYYCARDILDYWGQGTTVT VSS27 Hyal2F-VL DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGDTYLHWYQQKPGQPPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHVPWTFGGGTKVEIKReferences1. Sun et al., Nature, 2023, 615: 158-167.2. Sharma et al., Cell, 2017, 168:707-23.
Claims
What is claimed is:
1. An antibody or antigen binding fragment thereof that binds Hyaluronidase-2 and comprises a set of 6 CDRs set forth in SEQ ID NOs: 2-7.
2. The antibody or antigen binding fragment thereof of claim 1 , comprising a heavy chain variable region that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 8.
3. The antibody of antigen binding fragment thereof of claim 1 , comprising a heavy chain variable region set forth in SEQ ID NO: 8.
4. The antibody or antigen binding fragment thereof of claim 1 , comprising a light chain variable region that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 9.
5. The antibody or antigen binding fragment thereof of claim 1 , comprising a light chain variable region set forth in SEQ ID NO: 9.
6. The antibody or antigen binding fragment of claim 1, comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9.
7. The antibody or antigen binding fragment thereof of claim 1 , comprising a heavy chain variable region that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24 or SEQ ID NO: 26.
8. The antibody of antigen binding fragment thereof of claim 1 , comprising a heavy chain variable region set forth in SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24 or SEQ ID NO: 26.
9. The antibody or antigen binding fragment thereof of claim 1 , comprising a light chain variable region that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27.
10. The antibody or antigen binding fragment thereof of claim 1, comprising a light chain variable region set forth in SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27.
11. The antibody or antigen binding fragment thereof claim 1 , comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 20 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 21.
12. The antibody or antigen binding fragment thereof of claim 1, comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 22 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 23.
13. The antibody or antigen binding fragment thereof of claim 1, comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 24 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 25.
14. The antibody or antigen binding fragment thereof of claim 1, comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 26 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 27.
15. The antibody of any one of claims 1-14, that is a humanized antibody.
16. The antibody of any one of claims 1-14, that is a human antibody.
17. The antibody of any one of claims 1 -16, that is an IgG.
18. The antibody of any one of claims 1-17, comprising an Fc region.
19. An antibody or antigen binding fragment thereof that binds to Hyaluronidase-2 comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), wherein the CDR-H1, CDR-H2, and CDR-H3 are present in a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 8 and wherein the CDR-L1, CDR-L2, and CDR-L3 are present in a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 9.
20. An antibody or antigen binding fragment thereof that binds to Hyaluronidase-2 comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), wherein the CDR-H1, CDR-H2, and CDR-H3 are present in a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 20 and wherein the CDR-L1, CDR-L2, and CDR-L3 are present in a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 21.
21. An antibody or antigen binding fragment thereof that binds to Hyaluronidase-2 comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), wherein the CDR-H1, CDR-H2, and CDR-H3 are present in a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 22 and wherein the CDR-L1, CDR-L2, and CDR-L3 are present in a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 23.
22. An antibody or antigen binding fragment thereof that binds to Hyaluronidase-2 comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), wherein the CDR-H1, CDR-H2, and CDR-H3 are present in a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 24 and wherein the CDR-L1, CDR-L2, and CDR-L3 are present in a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 25.
23. An antibody or antigen binding fragment thereof that binds to Hyaluronidase-2 comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), wherein the CDR-H1,CDR-H2, and CDR-H3 are present in a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 26 and wherein the CDR-L1, CDR-L2, and CDR-L3 are present in a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 27.
24. The antibody or antigen binding fragment of any one of claims 19-23, wherein:the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to Kabat;the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to Chothia;the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to IMGT;the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to AbM;the CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to Contact; orthe CDR-H1, CDR-H2, and CDR-H3, and the CDR-L1, CDR-L2, and CDR-L3 are defined according to Honneger (AHo).
25. The antibody or antigen binding fragment of any one of claims 19-23, wherein the set of 6 CDRs are set forth in SEQ ID NOs: 2-7.
26. An antibody-drug conjugate comprising the antibody of any one of claims 1-25 conjugated to a cytotoxic agent.
27. The antibody-drug conjugate of claim 26, wherein the cytotoxic agent is a dihydrofolate reductase inhibitor, a thymidylate synthase inhibitor, a DNA intercalator, a DNA cleaver, a topoisomerase inhibitor, anthracycline, vinca, mitomycin, bleomycin, a cytotoxic nucleoside, a pteridine, a diynene, a podophyllotoxin, a dolastatin, a maytansinoid, a differentiation inducer, or a taxol.
28. The antibody-drug conjugate of claim 26, wherein the cytotoxic agent is a chemotherapeutic agent.
29. The antibody-drug conjugate of claim 28, wherein the chemotherapeutic agent is methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin, doxorubicin, mitomycin C, mitomycin A, caminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vinblastine, vincristine, vindesine, taxanes including taxol, taxotere retinoic acid, butyric acid, N8-acetyl spermidine, camptothecin, calicheamicin, esperamicin, ene-diynes, duocarmycin A, duocarmycin SA,calicheamicin, camptothecin, maytansinoids (including DM1), monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), or maytansinoids (DM4).
30. The antibody-drug conjugate of claim 28, wherein the antibody is conjugated with Doxorubicin, Docetaxel (Taxotere), Cisplatin, Gemcitabine, Carboplatin, Etoposide, Cyclophosphamide, Epirubicin, Vincristine, Methotrexate, 5-fluoroucil, or Mitomycin C.
31. The antibody-drug conjugate of claim 28, wherein the antibody is conjugated with PNU anthracycline, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), duocarmycin, calicheamicin, pyrrolobenzodiazepine, or SN-38.
32. A method of treating cancer in a subject in need thereof, comprising administering the antibody-drug conjugate of any one of claims 26-31 to the subject.
33. The method of claim 32, wherein the cancer is bladder cancer, prostate cancer, breast cancer, brain cancer or lung cancer.
